Nitrous

Sources

14 strong · 32 moderate · 7 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked

273

273inconclusive

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated

Apr 26, 2026 · pipeline-v5

Values approved

102/102 (100%)

Data points an editor reviewed and accepted for publication.

Value Provenance

Dosing

inhaledtrace

Field	Published	AI Proposed	Confidence
Threshold	4 g	4 g	medium
Low	4–8 g	4–8 g	medium
Common	8–16 g	8–16 g	medium
Strong	16–24 g	16–24 g	medium
Heavy	24+ g	24+ g	medium
Editorial	Dose values from existing database (community-curated, originally sourced from harm reduction community data). The 'g' unit refers to mass of N₂O gas, where a standard culinary charger contains 8g. No published literature expresses recreational N₂O doses in grams — clinical literature uses percentage concentration (e.g., 25%, 50%, 70%). These gram-based values reflect community convention for cartridge-based recreational use and should be verified by editorial review.
	ReasoningReasoning Dose values from existing database (community-curated, originally sourced from harm reduction community data). The 'g' unit refers to mass of N₂O gas, where a standard culinary charger contains 8g. No published literature expresses recreational N₂O doses in grams — clinical literature uses percentage concentration (e.g., 25%, 50%, 70%). These gram-based values reflect community convention for cartridge-based recreational use and should be verified by editorial review. Evidence basis: community_consensus_large

Duration

inhaled

Field	Published	AI Proposed	Confidence
Onsettrace	5–10 seconds	5–10 seconds	high
Editorial	Onset within 5-10 seconds is consistent with published pharmacokinetics (blood:gas partition coefficient ~0.47, Lew et al. 2018) and existing database values. Near-instantaneous alveolar-blood equilibration drives this rapid onset.
	ReasoningReasoning Onset within 5-10 seconds is consistent with published pharmacokinetics (blood:gas partition coefficient ~0.47, Lew et al. 2018) and existing database values. Near-instantaneous alveolar-blood equilibration drives this rapid onset. Evidence basis: controlled_human_study
Come uptrace	5–10 seconds	5–10 seconds	medium
Editorial	Come-up of 5-10 seconds from existing database values, consistent with the rapid blood-brain equilibration driven by low blood:gas partition coefficient.
	ReasoningReasoning Come-up of 5-10 seconds from existing database values, consistent with the rapid blood-brain equilibration driven by low blood:gas partition coefficient. Evidence basis: community_consensus_large
Peaktrace	15–30 seconds	15–30 seconds	medium
Editorial	Peak duration of 15-30 seconds from existing database values, consistent with survey data (Ehirim et al. 2018) reporting total effects lasting up to 5 minutes with the most intense period being very brief.
	ReasoningReasoning Peak duration of 15-30 seconds from existing database values, consistent with survey data (Ehirim et al. 2018) reporting total effects lasting up to 5 minutes with the most intense period being very brief. Evidence basis: community_consensus_large
Offsettrace	1–5 minutes	1–5 minutes	high
Editorial	Offset of 1-5 minutes from existing database values, consistent with published pharmacokinetics — N₂O is eliminated >99% via pulmonary exhalation with near-complete clinical recovery within minutes (Gernez et al. 2023, Lew et al. 2018).
	ReasoningReasoning Offset of 1-5 minutes from existing database values, consistent with published pharmacokinetics — N₂O is eliminated >99% via pulmonary exhalation with near-complete clinical recovery within minutes (Gernez et al. 2023, Lew et al. 2018). Evidence basis: controlled_human_study
Totaltrace	1–5 minutes	1–5 minutes	high
Editorial	Total subjective duration of 1-5 minutes from existing database values, corroborated by Ehirim et al. 2018 survey data (effects lasting up to 5 minutes) and consistent with the pharmacokinetic profile (blood:gas partition coefficient ~0.47).
	ReasoningReasoning Total subjective duration of 1-5 minutes from existing database values, corroborated by Ehirim et al. 2018 survey data (effects lasting up to 5 minutes) and consistent with the pharmacokinetic profile (blood:gas partition coefficient ~0.47). Evidence basis: community_consensus_large
After effectstrace	5–15 minutes	5–15 minutes	medium
Editorial	Aftereffects of 5-15 minutes reflecting residual light-headedness and mild dizziness after subjective effects resolve. Clinical guidelines recommend supplemental O₂ for 2-5 minutes post-cessation to address diffusion hypoxia (Lew et al. 2018).
	ReasoningReasoning Aftereffects of 5-15 minutes reflecting residual light-headedness and mild dizziness after subjective effects resolve. Clinical guidelines recommend supplemental O₂ for 2-5 minutes post-cessation to address diffusion hypoxia (Lew et al. 2018). Evidence basis: community_consensus_large

Safety

Toxicity Profiletrace

Field	Published	AI Proposed	Confidence
Acute	low	low	high
Chronic	high	high	high
Organs Affected	nervous_system, spinal_cord, hematological, cardiovascular	nervous_system, spinal_cord, hematological, cardiovascular	high
Editorial	Acute: No LD50 established; not directly cytotoxic; deaths attributable to asphyxiation only (van Amsterdam et al. 2022). Chronic: Oussalah et al. 2019 meta-analysis (n=100) documents SCD in 28%, myelopathy 26%, polyneuropathy 23% of symptomatic cases. Tani et al. 2019 demonstrates unique axonal dysfunction distinct from pure B12 deficiency. Multiple independent case series confirm organ damage at recreational doses across young populations.
	ReasoningReasoning Acute: No LD50 established; not directly cytotoxic; deaths attributable to asphyxiation only (van Amsterdam et al. 2022). Chronic: Oussalah et al. 2019 meta-analysis (n=100) documents SCD in 28%, myelopathy 26%, polyneuropathy 23% of symptomatic cases. Tani et al. 2019 demonstrates unique axonal dysfunction distinct from pure B12 deficiency. Multiple independent case series confirm organ damage at recreational doses across young populations. Evidence basis: systematic_review

Dependence Profiletrace

Field	Published	AI Proposed	Confidence
Physical	negligible	negligible	medium
Psychological	low	low	medium
Compulsive Redosing	moderate	moderate	medium
Dose Escalation	low	low	medium
Editorial	Physical and psychological dependence rated low per existing database values, consistent with Brunt et al. 2022 narrative review and Diesing & Neu 2025 ICD-10 assessment. Compulsive redosing risk elevated to moderate because the ultra-short duration inherently promotes repeated administration within sessions, and case reports document patterns of escalating session frequency (Brunt et al. 2022, Ehirim et al. 2018).
	ReasoningReasoning Physical and psychological dependence rated low per existing database values, consistent with Brunt et al. 2022 narrative review and Diesing & Neu 2025 ICD-10 assessment. Compulsive redosing risk elevated to moderate because the ultra-short duration inherently promotes repeated administration within sessions, and case reports document patterns of escalating session frequency (Brunt et al. 2022, Ehirim et al. 2018). Evidence basis: published_case_series

Withdrawal Profiletrace

Field	Published	AI Proposed	Confidence
Severity	none	none	medium
Symptoms	—	—	medium
Fatal	No	No	medium
Medical Supervision	Not required	Not required	medium
Editorial	No formal withdrawal syndrome has been characterised for N₂O in published literature. The absence of significant physical dependence and the gas's rapid elimination make classical withdrawal unlikely.
	ReasoningReasoning No formal withdrawal syndrome has been characterised for N₂O in published literature. The absence of significant physical dependence and the gas's rapid elimination make classical withdrawal unlikely. Evidence basis: published_case_series

Tolerance Profiletrace

Field	Published	AI Proposed	Confidence
Buildup	moderate	moderate	low
Half-life	5 days	5 days	low
Full Reset	10 days	10 days	low
Cross-tolerances	—	—	low
Editorial	Tolerance values carried forward from existing database (community-curated). These specific values (5-day half-life, 10-day full reset) lack published primary source support and should be flagged for editorial verification. The moderate buildup rate is consistent with community consensus that tolerance develops with repeated use but is not as rapid as classical psychedelic tachyphylaxis.
	ReasoningReasoning Tolerance values carried forward from existing database (community-curated). These specific values (5-day half-life, 10-day full reset) lack published primary source support and should be flagged for editorial verification. The moderate buildup rate is consistent with community consensus that tolerance develops with repeated use but is not as rapid as classical psychedelic tachyphylaxis. Evidence basis: community_consensus_large

Effects & Profile

Contraindications

Field	Published	AI Proposed	Confidence
metabolic vitamin B12 deficiencytrace	absolute	absolute	high
Editorial	Strong evidence from Oussalah et al. 2019 meta-analysis, multiple case series, and clinical anaesthesia guidelines (Lew et al. 2018, Huang & Johnson 2016, Sanders et al. 2008). Unanimously recognised as absolute contraindication.
	ReasoningReasoning Strong evidence from Oussalah et al. 2019 meta-analysis, multiple case series, and clinical anaesthesia guidelines (Lew et al. 2018, Huang & Johnson 2016, Sanders et al. 2008). Unanimously recognised as absolute contraindication.
respiratory pneumothoraxtrace	absolute	absolute	high
Editorial	Well-established clinical anaesthesia contraindication documented in Sanders et al. 2008, Lew et al. 2018, and standard anaesthesia textbooks. Mechanism is based on differential gas solubility physics.
	ReasoningReasoning Well-established clinical anaesthesia contraindication documented in Sanders et al. 2008, Lew et al. 2018, and standard anaesthesia textbooks. Mechanism is based on differential gas solubility physics.
other bowel obstructiontrace	absolute	absolute	high
Editorial	Established clinical contraindication from Sanders et al. 2008 and Lew et al. 2018. Same mechanism as pneumothorax contraindication.
	ReasoningReasoning Established clinical contraindication from Sanders et al. 2008 and Lew et al. 2018. Same mechanism as pneumothorax contraindication.
other middle ear diseasetrace	absolute	absolute	high
Editorial	Established clinical anaesthesia contraindication from Sanders et al. 2008 and Lew et al. 2018.
	ReasoningReasoning Established clinical anaesthesia contraindication from Sanders et al. 2008 and Lew et al. 2018.
other recent ophthalmic surgery with intraocular gastrace	absolute	absolute	high
Editorial	Well-documented clinical contraindication from Huang & Johnson 2016 and standard anaesthesia guidelines.
	ReasoningReasoning Well-documented clinical contraindication from Huang & Johnson 2016 and standard anaesthesia guidelines.
neurological pre-existing peripheral neuropathy or myelopathytrace	relative	relative	medium
Editorial	Clinical caution supported by Lew et al. 2018 and the finding by Tani et al. 2019 that N₂O causes direct axonal toxicity independent of B12 status.
	ReasoningReasoning Clinical caution supported by Lew et al. 2018 and the finding by Tani et al. 2019 that N₂O causes direct axonal toxicity independent of B12 status.
pregnancy breastfeeding first trimester pregnancytrace	relative	relative	medium
Editorial	Animal teratogenicity data from Burm 2003. Clinical caution advised in Huang & Johnson 2016. No controlled human data demonstrating harm from brief exposures, but the methylation disruption mechanism provides biological plausibility.
	ReasoningReasoning Animal teratogenicity data from Burm 2003. Clinical caution advised in Huang & Johnson 2016. No controlled human data demonstrating harm from brief exposures, but the methylation disruption mechanism provides biological plausibility.

Timeline Phases

inhaled

Field	Published	AI Proposed	Confidence
Onsettrace	5–10 sec(i=0.05)	5–10 sec(i=0.05)	medium
Editorial	Duration values derived from existing database data (onset 5-10s, come-up 5-10s, peak 15-30s, offset 1-5 min, total 1-5 min) which are consistent with published pharmacokinetics (blood:gas partition coefficient ~0.47, Lew et al. 2018) and recreational survey data (Ehirim et al. 2018 reporting effects lasting up to 5 minutes). The extremely rapid onset/offset reflects N₂O's near-instantaneous alveolar-blood equilibration and pulmonary elimination.
	ReasoningReasoning Duration values derived from existing database data (onset 5-10s, come-up 5-10s, peak 15-30s, offset 1-5 min, total 1-5 min) which are consistent with published pharmacokinetics (blood:gas partition coefficient ~0.47, Lew et al. 2018) and recreational survey data (Ehirim et al. 2018 reporting effects lasting up to 5 minutes). The extremely rapid onset/offset reflects N₂O's near-instantaneous alveolar-blood equilibration and pulmonary elimination.
Come uptrace	5–10 sec(i=0.30)	5–10 sec(i=0.30)	medium
Editorial	Duration values derived from existing database data (onset 5-10s, come-up 5-10s, peak 15-30s, offset 1-5 min, total 1-5 min) which are consistent with published pharmacokinetics (blood:gas partition coefficient ~0.47, Lew et al. 2018) and recreational survey data (Ehirim et al. 2018 reporting effects lasting up to 5 minutes). The extremely rapid onset/offset reflects N₂O's near-instantaneous alveolar-blood equilibration and pulmonary elimination.
	ReasoningReasoning Duration values derived from existing database data (onset 5-10s, come-up 5-10s, peak 15-30s, offset 1-5 min, total 1-5 min) which are consistent with published pharmacokinetics (blood:gas partition coefficient ~0.47, Lew et al. 2018) and recreational survey data (Ehirim et al. 2018 reporting effects lasting up to 5 minutes). The extremely rapid onset/offset reflects N₂O's near-instantaneous alveolar-blood equilibration and pulmonary elimination.
Peaktrace	15–30 sec(i=1.00)	15–30 sec(i=1.00)	medium
Editorial	Duration values derived from existing database data (onset 5-10s, come-up 5-10s, peak 15-30s, offset 1-5 min, total 1-5 min) which are consistent with published pharmacokinetics (blood:gas partition coefficient ~0.47, Lew et al. 2018) and recreational survey data (Ehirim et al. 2018 reporting effects lasting up to 5 minutes). The extremely rapid onset/offset reflects N₂O's near-instantaneous alveolar-blood equilibration and pulmonary elimination.
	ReasoningReasoning Duration values derived from existing database data (onset 5-10s, come-up 5-10s, peak 15-30s, offset 1-5 min, total 1-5 min) which are consistent with published pharmacokinetics (blood:gas partition coefficient ~0.47, Lew et al. 2018) and recreational survey data (Ehirim et al. 2018 reporting effects lasting up to 5 minutes). The extremely rapid onset/offset reflects N₂O's near-instantaneous alveolar-blood equilibration and pulmonary elimination.
Resolutiontrace	60–300 sec(i=0.20)	60–300 sec(i=0.20)	medium
Editorial	Duration values derived from existing database data (onset 5-10s, come-up 5-10s, peak 15-30s, offset 1-5 min, total 1-5 min) which are consistent with published pharmacokinetics (blood:gas partition coefficient ~0.47, Lew et al. 2018) and recreational survey data (Ehirim et al. 2018 reporting effects lasting up to 5 minutes). The extremely rapid onset/offset reflects N₂O's near-instantaneous alveolar-blood equilibration and pulmonary elimination.
	ReasoningReasoning Duration values derived from existing database data (onset 5-10s, come-up 5-10s, peak 15-30s, offset 1-5 min, total 1-5 min) which are consistent with published pharmacokinetics (blood:gas partition coefficient ~0.47, Lew et al. 2018) and recreational survey data (Ehirim et al. 2018 reporting effects lasting up to 5 minutes). The extremely rapid onset/offset reflects N₂O's near-instantaneous alveolar-blood equilibration and pulmonary elimination.
Afterglowtrace	300–900 sec(i=0.05)	300–900 sec(i=0.05)	medium
Editorial	Duration values derived from existing database data (onset 5-10s, come-up 5-10s, peak 15-30s, offset 1-5 min, total 1-5 min) which are consistent with published pharmacokinetics (blood:gas partition coefficient ~0.47, Lew et al. 2018) and recreational survey data (Ehirim et al. 2018 reporting effects lasting up to 5 minutes). The extremely rapid onset/offset reflects N₂O's near-instantaneous alveolar-blood equilibration and pulmonary elimination.
	ReasoningReasoning Duration values derived from existing database data (onset 5-10s, come-up 5-10s, peak 15-30s, offset 1-5 min, total 1-5 min) which are consistent with published pharmacokinetics (blood:gas partition coefficient ~0.47, Lew et al. 2018) and recreational survey data (Ehirim et al. 2018 reporting effects lasting up to 5 minutes). The extremely rapid onset/offset reflects N₂O's near-instantaneous alveolar-blood equilibration and pulmonary elimination.

Dose Tier Summaries

thresholdtrace

medium

At threshold doses (~4 g inhaled, approximately half a standard 8 g cartridge), effects are subtle and easily dismissed: a faint light-headedness, mild warmth, and a brief flicker of mood elevation lasting only seconds. Some users report a slight tingling sensation in the extremities and a momentary sense of bodily lightness. Physically, mild dizziness may be perceptible. Motor control and cognition remain essentially intact. The experience resolves within 30–60 seconds with no discernible aftereffects.

Editorial

Threshold dose of ~4g inhaled is from existing database values (community-curated). Subjective descriptions derived from clinical dental literature describing sub-anxiolytic concentrations (Emmanouil & Quock 2007) and survey data (Ehirim 2018).

Reasoning

Evidence basis: community_consensus_large

lighttrace

medium

At light doses (4–8 g inhaled, roughly one standard cartridge), anxiolysis and mild euphoria become clearly perceptible. A gentle dissociative quality emerges — slight detachment from surroundings, enhanced appreciation for music, and a feeling of floating or bodily lightness. Tactile sensations may feel subtly enhanced. Physically, dizziness is noticeable, and a warm tingling spreads through the body. Motor control is mildly impaired — standing is inadvisable. Cognitive function is slightly dulled but conversation remains possible. The total experience lasts approximately 1–3 minutes before returning to baseline.

Editorial

Light dose range (4–8g) from existing database values. Effects consistent with dental-range sub-anaesthetic concentrations (10–30%) described in Emmanouil & Quock 2007 and recreational survey data from Ehirim 2018.

Reasoning

Evidence basis: community_consensus_large

commontrace

medium

At common doses (8–16 g inhaled, one to two standard cartridges), the full characteristic N₂O experience manifests: pronounced euphoria, dissociation from the immediate environment, and significant time distortion — seconds may feel stretched or compressed. Auditory distortions are common, including a characteristic oscillating or "wah-wah" quality to sounds. Mild geometric visual disturbances and a strong sense of bodily lightness or floating emerge. Physically, dizziness is pronounced and motor control is substantially impaired — remaining seated is essential. Anxiety suppression is strong. Cognitive impairment is moderate, with slowed processing and impaired short-term memory. The peak lasts 15–30 seconds, with full resolution within 1–5 minutes.

Editorial

Common dose range (8–16g) from existing database values. Effects consistent with 30–50% concentration range described in clinical literature (Emmanouil & Quock 2007) and recreational survey data (Ehirim 2018).

Reasoning

Evidence basis: community_consensus_large

strongtrace

medium

At strong doses (16–24 g inhaled, two to three cartridges in rapid succession), pronounced dissociation dominates the experience. Depersonalisation and derealisation become prominent — the body and environment may feel profoundly unfamiliar. Auditory and visual distortions intensify, with geometry and pattern recognition emerging in closed-eye visuals. Amnesia for the peak experience is common. Time distortion is extreme. Physically, motor control is severely impaired and standing is dangerous. Transient numbness and heavy tingling pervade the body. Cognitive impairment is significant — coherent thought and speech are difficult during the peak. Risk of transient loss of consciousness increases. Effects resolve within 1–5 minutes, though mild disorientation may linger briefly.

Editorial

Strong dose range (16–24g) from existing database values. Effects consistent with higher sub-anaesthetic concentrations (50–70%) described in clinical literature and case reports.

Reasoning

Strong dose range (16–24g) from existing database values. Effects consistent with higher sub-anaesthetic concentrations (50–70%) described in clinical literature and case reports.

Evidence basis: community_consensus_large

heavytrace

medium

At heavy doses (>24 g inhaled, three or more cartridges in rapid succession), near-anaesthetic dissociation occurs. Complete disconnection from the external environment is possible, with intense closed-eye geometry, profound depersonalisation, and total amnesia for the peak. Some users report breakthrough dissociative experiences with dream-like or "hole"-like qualities. Physically, loss of consciousness is a significant risk. Motor control is entirely absent during the peak. The primary danger at this dose range is asphyxiation from oxygen displacement, particularly if inhalation continues without adequate air breathing between doses. Nausea may occur upon return to baseline. Effects resolve within 1–5 minutes, but repeated heavy dosing in rapid succession accumulates neurological risk through cobalamin inactivation.

Editorial

Heavy dose (>24g) from existing database values. Effects extrapolated from clinical descriptions of near-anaesthetic concentrations (>70%) and case reports of heavy recreational use patterns (Brunt et al. 2022).

Reasoning

History

current version

published Jun 4, 2026AI-generated—

versions

1 total

publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correction contact@psychedex.org

Sources

14 strong · 32 moderate · 7 weak

[1]
moderate
Past, present, and future of nitrous oxide
Lew V, McKay E, Maze M · 2018 · British Medical Bulletin
doi.org/10.1093/bmb/ldx050 pubmed 2952836730 claims checked30 inconclusive
[2]
moderate
Effects of anesthetics on mutant N-methyl-D-aspartate receptors expressed in Xenopus oocytes
Ogata J et al. · 2006 · Journal of pharmacology and experimental therapeutics
pubmed 166220409 claims checked9 inconclusive
[3]
moderate
Role of brain dynorphin in nitrous oxide antinociception in mice
Branda EM, Ramza JT, Cahill FJ, Tseng LF, Quock RM · 2000 · Pharmacology, biochemistry, and behavior
pubmed 106729729 claims checked9 inconclusive
[4]
moderate
Deletion of mu-opioid receptor in mice does not affect the minimum alveolar concentration of volatile anaesthetics and nitrous oxide-induced analgesia
Koyama T et al. · 2009 · British Journal of Anaesthesia
doi.org/10.1093/bja/aep246 pubmed 197673139 claims checked9 inconclusive
[5]
moderate
Mini-Review: A Brief History of Nitrous Oxide (N2O) Use in Neuropsychiatry
Gillman MA · 2019 · Current Drug Research Reviews
doi.org/10.2174/1874473711666181008163107 pubmed 3082917712 claims checked12 inconclusive
[6]
strong
A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression
Nagele P et al. · 2021 · Science Translational Medicine
doi.org/10.1126/scitranslmed.abe1376 pubmed 341082473 claims checked3 inconclusive
[7]
strong
Nitrous oxide for the treatment of depression: a systematic review and meta-analysis
Gill K et al. · 2025 · EBioMedicine
doi.org/10.1016/j.ebiom.2025.106023 pubmed 413262909 claims checked9 inconclusive
[8]
moderate
Mechanisms Involved in the Neurotoxicity and Abuse Liability of Nitrous Oxide: A Narrative Review
Brunt TM, van den Brink W, van Amsterdam J · 2022 · International Journal of Molecular Sciences
doi.org/10.3390/ijms232314747 pubmed 3649907212 claims checked12 inconclusive
[9]
strong
Global Burden Related to Nitrous Oxide Exposure in Medical and Recreational Settings: A Systematic Review and Individual Patient Data Meta-Analysis
Oussalah A et al. · 2019 · Journal of Clinical Medicine
doi.org/10.3390/jcm8040551 pubmed 310186139 claims checked9 inconclusive
[10]
weak
Nitrous oxide induced subacute combined degeneration of the spine cord: A case report
Wang S et al. · 2024 · Medicine
doi.org/10.1097/md.0000000000037032 pubmed 383353796 claims checked6 inconclusive
[11]
weak
Circular 006/2023: Control of nitrous oxide under the Misuse of Drugs Act 1971
UK Home Office · 2023
linkno claims checked
[12]
moderate
The minimum alveolar concentration of nitrous oxide in man
Hornbein TF, Eger EI, Winter PM et al. · 1982 · Anesthesia and Analgesia
pubmed 720125412 claims checked12 inconclusive
[13]
moderate
Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of alpha2B adrenoceptors
Sawamura S, Kingery WS, Davies MF et al. · 2000 · Journal of Neuroscience
pubmed 111250029 claims checked9 inconclusive
[14]
strong
Biologic effects of nitrous oxide: a mechanistic and toxicologic review
Sanders RD, Weimann J, Maze M · 2008 · Anesthesiology
doi.org/10.1097/aln.0b013e3181870a17 pubmed 188130516 claims checked6 inconclusive
[15]
strong
Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial
Nagele P, Duma A, Kopec M, Gebara MA, Parsoei A, Walker M, Janski A, Panagopoulos VN, Cristancho P, Miller JP, Zorumski CF, Conway CR · 2015 · Biological Psychiatry
doi.org/10.1016/j.biopsych.2014.11.016 pubmed 255771646 claims checked6 inconclusive
[16]
strong
Antidepressant Effects of Nitrous Oxide in Major Depressive Disorder: A Phase 2b Randomized Clinical Trial
Myles PS, Kulkarni J, Kasza J et al. · 2025 · Biological Psychiatry Global Open Science
doi.org/10.1016/j.bpsgos.2025.100504 pubmed 40503328no claims checked
[17]
strong
The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial
Myles PS, Leslie K, Chan MT et al. · 2014 · Lancet
pubmed 251427086 claims checked6 inconclusive
[18]
strong
Nitrous Oxide and Serious Long-term Morbidity and Mortality in the ENIGMA-II Trial
Leslie K, Myles PS, Kasza J et al. · 2015 · Anesthesiology
doi.org/10.1097/aln.0000000000000908 pubmed 265013873 claims checked3 inconclusive
[19]
strong
Severe Nausea and Vomiting in the Evaluation of Nitrous Oxide in the Gas Mixture for Anesthesia II Trial
Myles PS, Chan MT, Kasza J et al. · 2016 · Anesthesiology
doi.org/10.1097/aln.0000000000001057 pubmed 26904965no claims checked
[20]
moderate
Nitrous oxide (N2O) requires the N-methyl-D-aspartate receptor for its action in Caenorhabditis elegans
Nagele P, Metz LB, Crowder CM · 2004 · PNAS
pubmed 151595326 claims checked6 inconclusive
[21]
moderate
Protein crystallography under xenon and nitrous oxide pressure: comparison with in vivo pharmacology studies
Colloc'h N et al. · 2007 · Biophysical journal
pubmed 170281306 claims checked6 inconclusive
[22]
moderate
Nitrous oxide-induced NO-dependent neuronal release of beta-endorphin from the rat arcuate nucleus and periaqueductal gray
Ohgami Y, Chung E, Quock RM · 2010 · Brain Research
doi.org/10.1016/j.brainres.2010.10.010 pubmed 209372633 claims checked3 inconclusive
[23]
moderate
Advances in understanding the actions of nitrous oxide
Emmanouil DE, Quock RM · 2007 · Anesthesia progress
pubmed 173525296 claims checked6 inconclusive
[24]
moderate
A new mechanistic approach for the treatment of chronic neuropathic pain with nitrous oxide integrated from a systems biology narrative review
Bessiere B et al. · 2021 · Medical Gas Research
doi.org/10.4103/2045-9912.310058 pubmed 336423363 claims checked3 inconclusive
[25]
moderate
Nitrous oxide activates layer 5 prefrontal neurons via SK2 channel inhibition for antidepressant effect
Cichon J, Joseph TT, Lu X et al. · 2025 · Nature Communications
doi.org/10.1038/s41467-025-57951-y pubmed 4018093115 claims checked15 inconclusive
[26]
moderate
Nitrous Oxide, a Rapid Antidepressant, Has Ketamine-like Effects on Excitatory Transmission in the Adult Hippocampus
Izumi Y, Hsu FF, Conway CR et al. · 2022 · Biological Psychiatry
doi.org/10.1016/j.biopsych.2022.06.016 pubmed 360501376 claims checked6 inconclusive
[27]
moderate
Nitrous Oxide Abuse: Clinical Outcomes, Pharmacology, Pharmacokinetics, Toxicity and Impact on Metabolism
Gernez É et al. · 2023 · Toxics
doi.org/10.3390/toxics11120962 pubmed 381333639 claims checked9 inconclusive
[28]
moderate
Antinociceptive response to nitrous oxide is mediated by supraspinal opiate and spinal alpha 2 adrenergic receptors in the rat
Guo TZ, Poree L, Golden W et al. · 1996 · Anesthesiology
pubmed 88735559 claims checked9 inconclusive
[29]
moderate
Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy
Zorumski CF, Nägele P, Mennerick SJ, Conway CR · 2015 · Frontiers in Psychiatry
doi.org/10.3389/fpsyt.2015.00172 pubmed 26696909no claims checked
[30]
moderate
Persistent Brain Connectivity Changes in Healthy Volunteers Following Nitrous Oxide Inhalation
Palanca BJA, Conway CR, Zeffiro T et al. · 2023 · Biological Psychiatry Global Open Science
doi.org/10.1016/j.bpsgos.2023.01.006 pubmed 37881568no claims checked
[31]
strong
Nitrous oxide added at the end of isoflurane anesthesia hastens early recovery without increasing the risk for postoperative nausea and vomiting: a randomized clinical trial
Mraovic B, Simurina T, Gan TJ · 2018 · Canadian Journal of Anaesthesia
doi.org/10.1007/s12630-017-1013-y pubmed 291507823 claims checked3 inconclusive
[32]
moderate
Plasma Methionine and Clinical Severity in Nitrous Oxide Consumption
Gernez E, Deheul S, Tard C et al. · 2022 · Toxics
doi.org/10.3390/toxics11010012 pubmed 36668738no claims checked
[33]
strong
Efficacy and safety of nitrous oxide for patients with treatment-resistant depression, a randomized controlled trial
Yan D et al. · 2022 · Psychiatry Research
doi.org/10.1016/j.psychres.2022.114867 pubmed 361915563 claims checked3 inconclusive
[34]
strong
Brain function changes reveal rapid antidepressant effects of nitrous oxide for treatment-resistant depression: Evidence from task-state EEG
Shao X et al. · 2023 · Psychiatry Research
doi.org/10.1016/j.psychres.2023.115072 pubmed 36791487no claims checked
[35]
strong
Empirical evidence for the neurocognitive effect of nitrous oxide as an adjunctive therapy in patients with treatment resistant depression
Liu J et al. · 2023 · Psychiatry Research
doi.org/10.1016/j.psychres.2023.115326 pubmed 373906013 claims checked3 inconclusive
[36]
strong
Proof-of-concept randomized controlled trial of single-session nitrous oxide treatment for refractory bipolar depression
Kim WSH et al. · 2023 · Bipolar Disorders
doi.org/10.1111/bdi.13288 pubmed 36579458no claims checked
[37]
moderate
A single nitrous oxide (N2O) exposure leads to persistent alleviation of neuropathic pain in rats
Bessière B et al. · 2010 · The Journal of Pain
doi.org/10.1016/j.jpain.2009.05.003 pubmed 197832233 claims checked3 inconclusive
[38]
moderate
Chronic postsurgical pain after nitrous oxide anesthesia
Chan MTV, Wan ACM, Gin T, Leslie K, Myles PS · 2011 · Pain
doi.org/10.1016/j.pain.2011.07.015 pubmed 21889262no claims checked
[39]
moderate
Increasing recreational nitrous oxide use: Should we worry? A narrative review
van Amsterdam J, Nabben T, van den Brink W · 2022 · Journal of Psychopharmacology
doi.org/10.1177/02698811221082442 pubmed 356785123 claims checked3 inconclusive
[40]
weak
Nitrous oxide abuse in the emergency practice, and Review of toxicity mechanisms and potential markers
Joncquel Chevalier-Curt M, Grzych G, Tard C et al. · 2022 · Food and Chemical Toxicology
doi.org/10.1016/j.fct.2022.112894 pubmed 352197653 claims checked3 inconclusive
[41]
weak
Nitrous oxide induced subacute combined degeneration with longitudinally extensive myelopathy with inverted V-sign on spinal MRI: a case report and literature review
Yuan JL, Wang SK, Jiang T, Hu WL · 2017 · BMC Neurology
doi.org/10.1186/s12883-017-0990-3 pubmed 292820013 claims checked3 inconclusive
[42]
moderate
Elucidating Unique Axonal Dysfunction Between Nitrous Oxide Abuse and Vitamin B12 Deficiency
Tani J et al. · 2019 · Frontiers in Neurology
doi.org/10.3389/fneur.2019.00704 pubmed 313546073 claims checked3 inconclusive
[43]
weak
Nitrous oxide abuse induced subacute combined degeneration despite patient initiated B12 supplementation
Temple C, Horowitz BZ · 2022 · Clinical Toxicology
doi.org/10.1080/15563650.2022.2046772 pubmed 352535673 claims checked3 inconclusive
[44]
moderate
Megaloblastic haemopoiesis in patients receiving nitrous oxide
Amess JA et al. · 1978 · Lancet
pubmed 797093 claims checked3 inconclusive
[45]
moderate
Human bone marrow biochemical function and megaloblastic hematopoiesis after nitrous oxide anesthesia
O'Sullivan H, Jennings F, Ward K et al. · 1981 · Anesthesiology
pubmed 69755883 claims checked3 inconclusive
[46]
moderate
Occupational hazards of inhalational anaesthetics
Burm AG · 2003 · Best Practice & Research Clinical Anaesthesiology
pubmed 127515546 claims checked6 inconclusive
[47]
moderate
Commentary on Nitrous Oxide: Weighing the Toxic Neuropsychiatric Effects of Abuse Against Potential Therapeutic Benefits for Psychiatric Disorders
Garakani A · 2025 · Journal of Psychiatric Practice
doi.org/10.1097/pra.0000000000000854 pubmed 404406763 claims checked3 inconclusive
[48]
weak
Double-sidedness of laughing gas on the N-methyl-d-aspartate receptor: A case report of acute psychosis associated with nitrous oxide-induced hyperhomocysteinemia
Kim S, Lee SH, Bang M · 2019 · Schizophrenia Research
doi.org/10.1016/j.schres.2019.02.006 pubmed 307958753 claims checked3 inconclusive
[49]
moderate
Life style drug laughing gas (nitrous oxide, N2O) and the dependency criteria according to ICD-10
Diesing D, Neu P · 2025 · Der Nervenarzt
doi.org/10.1007/s00115-024-01736-z pubmed 393119173 claims checked3 inconclusive
[50]
moderate
No Laughing Matter: Presence, Consumption Trends, Drug Awareness, and Perceptions of 'Hippy Crack' (Nitrous Oxide) among Young Adults in England
Ehirim EM, Naughton DP, Petróczi A · 2018 · Frontiers in Psychiatry
doi.org/10.3389/fpsyt.2017.00312 pubmed 294034003 claims checked3 inconclusive
[51]
moderate
Nitrous Oxide, From the Operating Room to the Emergency Department
Huang C, Johnson N · 2016 · Current Emergency and Hospital Medicine Reports
doi.org/10.1007/s40138-016-0092-3 pubmed 270737496 claims checked6 inconclusive
[52]
weak
Regulation of Nitrous Oxide: Australia, Belgium, Canada, China
Law Library of Congress · 2025
linkno claims checked
[53]
moderate
Incidence and pathogenesis of acute megaloblastic bone-marrow change in patients receiving intensive care
Amos RJ, Amess JA, Hinds CJ, Mollin DL · 1982 · Lancet
pubmed 61267093 claims checked3 inconclusive

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary36 claims36inconclusive

inconclusiveNitrous oxide (N₂O), commonly known as laughing gas, is a dissociative and depressant inhalational agent distinguished by the shortest duration of action among all psychoactive dissociatives — total subjective effects resolve within 1–5 minutes owing to a blood:gas partition coefficient of approximately 0.47, one of the lowest among inhaled anesthetics^[1]90%

Inconclusive

Abstract not available; cannot verify specific claims about duration, partition coefficient, or comparative ranking.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveIts minimum alveolar concentration (MAC) of 1.04 ± 0.10 atm renders it incapable of producing full surgical anesthesia at standard atmospheric pressure.^[12]90%

Inconclusive

Abstract not available; scope confirms MAC = 1.04 atm is in scope but full text required for confirmation.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveFirst synthesized by Joseph Priestley in 1772 and explored extensively by Humphry Davy in the 1790s, N₂O holds the distinction of being the longest continuously used anesthetic agent in medicine — over 180 years of clinical service beginning with Horace Wells's dental application in 1844^[5]90%

Inconclusive

Abstract not available; key dates are within scope but '180 years' and 'longest used' framing cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveContemporary research significance centres on its rapid antidepressant properties: a Phase 2 crossover trial demonstrated that a single one-hour inhalation of 25% N₂O produced antidepressant efficacy comparable to 50% with fewer adverse effects in treatment-resistant major depression, and a 2025 systematic review and meta-analysis consolidated this evidence base.^[6]90%

Inconclusive

Abstract not available; scope confirms Phase 2 RCT is the right paper but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

Inconclusive

Abstract not available; scope confirms 2025 systematic review but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveN₂O acts primarily as a non-competitive NMDA receptor antagonist at a binding site mechanistically distinct from other anaesthetics — mutations in transmembrane segments TM3 and TM4 that abolish the effects of most volatile anaesthetics leave N₂O inhibition intact^[2]90%

Inconclusive

Abstract not available; TM3/TM4 mutation finding is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveAnalgesia is mediated through a parallel pathway: stimulation of endogenous dynorphin release via kappa opioid receptors combined with noradrenergic descending inhibition via brainstem nuclei and spinal alpha₂B adrenoceptors^[3]90%

Inconclusive

Abstract not available; dynorphin mediation is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

Inconclusive

Abstract not available; mu-opioid independence/kappa implication is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

Inconclusive

Abstract not available; noradrenergic/alpha2B pathway is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe dominant chronic risk is subacute combined degeneration of the spinal cord via irreversible oxidation of cobalamin — serum B₁₂ levels may remain normal despite clinically significant myelopathy, requiring homocysteine and methylmalonic acid for diagnosis^[9]90%

Inconclusive

Abstract not available; B12/SCD coverage is within scope but specific claim about normal serum B12 with myelopathy cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

Inconclusive

Abstract not available; case report scope covers SCD/B12 mechanism but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusivePhysical and psychological dependence liability are both low, though compulsive patterns with heavy daily use have been documented^[8]90%

Inconclusive

Abstract not available; dependence liability is within scope but specific verdict cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

Inconclusive

Abstract not available; cannot verify the specific pharmacokinetic claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveIts minimum alveolar concentration (MAC) of 1.04 ± 0.10 atm renders it incapable of producing full surgical anesthesia at standard atmospheric pressure.^[12]95%

Inconclusive

Abstract not available; cannot verify the specific MAC value against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the historical claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the Phase 2 trial findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the systematic review claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveN₂O acts primarily as a non-competitive pharmacological/nmda-receptor-antagonist at a binding site mechanistically distinct from other anaesthetics — mutations in transmembrane segments TM3 and TM4 that abolish the effects of most volatile anaesthetics leave N₂O inhibition intact^[2]95%

Inconclusive

Abstract not available; cannot verify the TM3/TM4 mutation findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the dynorphin/kappa-opioid pathway claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the mu-opioid knockout findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the noradrenergic/alpha₂B pathway claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the diagnostic biomarker claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the case report findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusivePhysical and psychological-dependence liability are both low, though compulsive patterns with heavy daily use have been documented. tolerance mechanisms in humans remain poorly characterised: no controlled tolerance studies have been published, and the specific timeline of tolerance development and reset lacks primary-source verification.^[8]95%

Inconclusive

Abstract not available; cannot verify the dependence liability characterisation against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveIts minimum alveolar concentration (MAC) of 1.04 ± 0.10 atm renders it incapable of producing full surgical anesthesia at standard atmospheric pressure.^[12]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

history21 claims21inconclusive

inconclusiveJoseph Priestley first synthesized nitrous oxide in 1772, adding it to the growing catalogue of 'factitious airs' under investigation by pneumatic chemists of the late eighteenth century^[5]90%

Inconclusive

Abstract not available; Priestley 1772 is within stated scope but 'factitious airs' terminology cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe demonstration was widely considered a failure (the patient reportedly cried out, though he later stated he felt no pain), and Wells's reputation suffered^[5]90%

Inconclusive

Abstract not available; Wells 1844 is within stated scope but specific narrative details cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveBy the 1930s, N₂O had become the mainstay of intrapartum pain relief, a role formalised with the development of premixed 50% N₂O/O₂ (Entonox) delivery systems^[14]85%

Inconclusive

Abstract available but only confirms N2O is the longest-serving anaesthetic. Does not address intrapartum use, the 1930s, or Entonox.

Nitrous oxide is the longest serving member of the anesthesiologist's pharmacologic armamentarium but remains a source of controversy because of fears over its adverse effects.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveIn 1994, the term 'Psychotropic Analgesic Nitrous Oxide' (PAN) was introduced to distinguish the non-anaesthetic concentration range (typically 25–50%) used for psychotropic and analgesic purposes from the higher concentrations employed for surgical anaesthesia.^[5]90%

Inconclusive

Abstract not available; PAN 1994 terminology is within stated scope but details cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveNagele and colleagues then conducted the first proof-of-concept randomised controlled trial demonstrating rapid antidepressant effects of a single one-hour N₂O inhalation in treatment-resistant major depression, published in 2015^[15]90%

Inconclusive

Abstract not available; scope confirms this is the proof-of-concept RCT but year (2015) and design details cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveBy 2025, a systematic review and meta-analysis had synthesised the accumulated antidepressant trial data, and a Phase 2b trial had extended investigation to major depressive disorder beyond treatment-resistant populations.^[7]90%

Inconclusive

Abstract not available; 2025 systematic review is within scope but the Phase 2b trial reference is not confirmed by this citation alone.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe ENIGMA trials represent the largest controlled investigations of N₂O safety: ENIGMA-II randomised 7,112 at-risk surgical patients to N₂O or nitrogen-based anaesthesia, finding no increase in cardiovascular mortality at one year but confirming significant postoperative nausea and vomiting risk.^[17]90%

Inconclusive

Abstract not available; n=7112 and no cardiovascular mortality increase are within scope but PONV confirmation cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveJoseph Priestley first synthesized nitrous oxide in 1772, adding it to the growing catalogue of "factitious airs" under investigation by pneumatic chemists of the late eighteenth century^[5]95%

Inconclusive

Abstract not available; cannot verify the 1772 synthesis historical claim against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe demonstration was widely considered a failure (the patient reportedly cried out, though he later stated he felt no pain), and Wells's reputation suffered^[5]95%

Inconclusive

Abstract not available; cannot verify the Wells demonstration outcome against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveBy the 1930s, N₂O had become the mainstay of intrapartum pain relief, a role formalised with the development of premixed 50% N₂O/O₂ (Entonox) delivery systems^[14]90%

Inconclusive

Abstract available but is a single generic sentence about N₂O as an anesthetic with adverse effects — does not address the 1930s intrapartum use or Entonox development history.

Nitrous oxide is the longest serving member of the anesthesiologist's pharmacologic armamentarium but remains a source of controversy because of fears over its adverse effects.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveIn 1994, the term "Psychotropic Analgesic Nitrous Oxide" (PAN) was introduced to distinguish the non-anaesthetic concentration range (typically 25–50%) used for psychotropic and analgesic purposes from the higher concentrations employed for surgical anaesthesia.^[5]95%

Inconclusive

Abstract not available; cannot verify the 1994 PAN nomenclature introduction against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the 2015 proof-of-concept RCT details against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the 2025 systematic review scope claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the ENIGMA-II trial details against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe demonstration was widely considered a failure (the patient reportedly cried out, though he later stated he felt no pain), and Wells's reputation suffered^[5]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveBy the 1930s, N₂O had become the mainstay of intrapartum pain relief, a role formalised with the development of premixed 50% N₂O/O₂ (Entonox) delivery systems^[14]90%

Inconclusive

Abstract describes N₂O as 'the longest serving member of the anesthesiologist's pharmacologic armamentarium' — consistent with a long history but provides no detail on the 1930s intrapartum role or Entonox.

Nitrous oxide is the longest serving member of the anesthesiologist's pharmacologic armamentarium but remains a source of controversy because of fears over its adverse effects.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

chemistry3 claims3inconclusive

inconclusiveThe blood:gas partition coefficient of approximately 0.47 is one of the lowest among inhaled anaesthetics — comparable only to xenon — and is the primary determinant of N₂O's extremely rapid onset (5–10 seconds) and offset (1–5 minutes)^[1]90%

Inconclusive

Abstract not available; partition coefficient and xenon comparison likely within scope but cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

Inconclusive

Abstract not available; cannot verify the partition coefficient and onset/offset timing claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

pharmacology57 claims57inconclusive

inconclusiveElimination occurs almost entirely via pulmonary exhalation, with greater than 99% of the administered dose exhaled unchanged.^[27]90%

Inconclusive

Abstract not available; pharmacokinetics coverage is within scope but '>99%' figure cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe MAC in humans is 1.04 ± 0.10 atm absolute^[12]90%

Inconclusive

Abstract not available; MAC = 1.04 atm is within scope but precise ± value cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveAt 1.55 atm (hyperbaric conditions), it produces muscle rigidity, laboured breathing, and diaphoresis.^[12]90%

Inconclusive

Abstract not available; muscle rigidity at 1.55 atm is within scope but full symptom list cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveNagele and colleagues provided in vivo genetic proof in Caenorhabditis elegans that the NMDA receptor subunit NMR-1 is required for N₂O's behavioural effects, confirming the receptor target established by earlier electrophysiological work^[20]90%

Inconclusive

Abstract not available; in vivo genetic NMDA proof is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveCritically, N₂O's inhibition of NMDA receptors is unaffected by mutations in transmembrane segments TM3 (NR1 F639A) and TM4 (NR2A A825W) that abolish the effects of most other volatile anaesthetics, demonstrating a mechanistically distinct binding site^[2]90%

Inconclusive

Abstract not available; TM3/TM4 mutation finding is within scope but specific residue labels and full anaesthetic list cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveX-ray crystallography has shown that N₂O binds to hydrophobic flexible cavities within protein monomers, at a site distinct from the ethanol/ketamine binding pocket.^[21]90%

Inconclusive

Abstract not available; structural binding data is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveOhgami and colleagues demonstrated that 70% N₂O significantly increases dialysate levels of β-endorphin in the arcuate nucleus and periaqueductal gray of rats via a nitric oxide (NO)-dependent mechanism — an effect blocked by the NO synthase inhibitor L-NAME^[22]90%

Inconclusive

Abstract not available; NO-dependent beta-endorphin release in ARC and PAG is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveHowever, the primary mediating peptide is dynorphin, not β-endorphin: Branda and colleagues demonstrated using antisera and peptidase inhibitors that dynorphin is the endogenous opioid responsible for N₂O antinociception in the mouse abdominal constriction test^[3]90%

Inconclusive

Abstract not available; dynorphin mediation is within scope but specific methodological details cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveConsistent with this, mu-opioid receptor knockout mice retain normal N₂O analgesia, implicating the kappa opioid receptor (KOR)/dynorphin system as the functional effector^[4]90%

Inconclusive

Abstract not available; mu-opioid independence is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveGuo and colleagues established a dual analgesic architecture: supraspinal opioid release combined with spinal alpha₂ adrenoceptor activation.^[28]90%

Inconclusive

Abstract not available; dual mechanism (supraspinal opioid + spinal alpha2) is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveSawamura and colleagues demonstrated using DBH-saporin lesioning in mice that this noradrenergic pathway is required for N₂O analgesia but not for its sedative effects — a critical mechanistic dissociation^[13]90%

Inconclusive

Abstract not available; noradrenergic pathway/sedation dissociation is within scope but DBH-saporin methodological detail cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe specific adrenoceptor subtype mediating this analgesic action is the alpha₂B receptor, distinct from the alpha₂A subtype targeted by exogenous agonists such as clonidine and dexmedetomidine.^[13]90%

Inconclusive

Abstract not available; alpha2B specificity is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveAnxiolysis may involve GABA-A receptor modulation at specific subunits, producing effects analogous to benzodiazepines, though this mechanism remains less well characterised than the analgesic pathways.^[23]90%

Inconclusive

Abstract not available; GABA-A anxiolytic mechanism is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveBessière and colleagues summarised additional analgesic targets: activation of TREK-1 (TWIK-related K⁺ channel 1) on first-order sensory neurons reduces neuronal excitability; blockade of voltage-dependent calcium channels attenuates synaptic transmission; and possible blockade of voltage-dependent sodium channels further contributes to peripheral and central analgesic effects.^[24]90%

Inconclusive

Abstract not available; TREK-1 and voltage-dependent channels are within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveCichon and colleagues demonstrated in 2025 that N₂O activates Layer 5 (L5) pyramidal neurons in the cingulate cortex via SK2 channel inhibition, independent of NMDA receptor function^[25]90%

Inconclusive

Abstract not available; SK2/L5 mechanism and NMDA independence are within scope but 'cingulate cortex' vs paper title 'prefrontal' discrepancy cannot be adjudicated without full text.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveIzumi and colleagues showed that N₂O has ketamine-like effects on excitatory glutamate transmission in the adult hippocampus, enhancing glutamate-mediated synaptic activity consistent with NMDA antagonism-mediated disinhibition of glutamatergic circuits.^[26]90%

Inconclusive

Abstract not available; ketamine-like hippocampal glutamate effects are within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusivePulmonary absorption is extremely rapid, driven by alveolar partial pressure gradients and facilitated by the exceptionally low blood:gas partition coefficient of approximately 0.47 — comparable only to xenon among clinically used anaesthetics^[1]90%

Inconclusive

Abstract not available; partition coefficient and xenon comparison likely in scope but cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveUpon abrupt cessation, N₂O diffuses rapidly from blood back into the alveoli, transiently diluting alveolar oxygen and producing diffusion hypoxia — a phenomenon requiring supplemental oxygen administration for 2–5 minutes in clinical settings.^[1]90%

Inconclusive

Abstract not available; diffusion hypoxia and oxygen supplementation likely within scope but cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveN₂O is 'very challenging to measure in biological matrices,' which is why indirect biomarkers — vitamin B₁₂, homocysteine, and methylmalonic acid (MMA) — are used diagnostically.^[27]90%

Inconclusive

Abstract not available; biomarker discussion is within scope but quoted phrase cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

Inconclusive

Abstract not available; cannot verify the C. elegans genetic findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the specific mutation data against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveX-ray crystallography has shown that N₂O binds to hydrophobic flexible cavities within protein monomers, at a site distinct from the ethanol/ketamine binding pocket.^[21]95%

Inconclusive

Abstract not available; cannot verify the crystallography findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveOhgami and colleagues demonstrated that 70% N₂O significantly increases dialysate levels of β-endorphins in the arcuate nucleus and periaqueductal gray of rats via a nitric oxide (NO)-dependent mechanism — an effect blocked by the NO synthase inhibitor L-NAME^[22]95%

Inconclusive

Abstract not available; cannot verify the β-endorphin/L-NAME findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the dynorphin antisera findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveConsistent with this, mu-opioid-receptor knockout mice retain normal N₂O analgesia, implicating the kappa opioid receptor (kappa-opioid-receptor)/dynorphin system as the functional effector^[4]95%

Inconclusive

Abstract not available; cannot verify the mu-opioid knockout analgesia findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveGuo and colleagues established a dual analgesic architecture: supraspinal opioid release combined with spinal alpha₂ adrenoceptor activation.^[28]95%

Inconclusive

Abstract not available; cannot verify the dual analgesic architecture claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the DBH-saporin lesioning findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the alpha₂B vs alpha₂A subtype specificity against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveAnxiolysis may involve gaba-a-receptor modulation at specific subunits, producing effects analogous to benzodiazepines, though this mechanism remains less well characterised than the analgesic pathways.^[23]95%

Inconclusive

Abstract not available; cannot verify the GABA-A anxiolysis mechanism claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the TREK-1/calcium/sodium channel claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the SK2 channel/L5 neuron findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveIzumi and colleagues showed that N₂O has Ketamine-like effects on excitatory glutamate transmission in the adult hippocampus, enhancing glutamate-mediated synaptic activity consistent with NMDA antagonism-mediated disinhibition of glutamatergic circuits.^[26]95%

Inconclusive

Abstract not available; cannot verify the hippocampal glutamate transmission findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the partition coefficient comparison with xenon against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveElimination occurs almost entirely via pulmonary exhalation, with greater than 99% of the administered dose exhaled unchanged.^[27]95%

Inconclusive

Abstract not available; cannot verify the >99% pulmonary elimination figure against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe MAC in humans is 1.04 ± 0.10 atm absolute^[12]95%

Inconclusive

Abstract not available; cannot verify the precise MAC value against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveAt 1.55 atm (hyperbaric conditions), it produces muscle rigidity, laboured breathing, and diaphoresis.^[12]95%

Inconclusive

Abstract not available; cannot verify the hyperbaric symptom data against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the diffusion hypoxia mechanism claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveN₂O is "very challenging to measure in biological matrices," which is why indirect biomarkers — vitamin B₁₂, homocysteine, and methylmalonic acid (MMA) — are used diagnostically.^[27]95%

Inconclusive

Abstract not available; cannot verify the measurement challenge and indirect biomarker claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveX-ray crystallography has shown that N₂O binds to hydrophobic flexible cavities within protein monomers, at a site distinct from the ethanol/ketamine binding pocket.^[21]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveGuo and colleagues established a dual analgesic architecture: supraspinal opioid release combined with spinal alpha₂ adrenoceptor activation.^[28]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveElimination occurs almost entirely via pulmonary exhalation, with greater than 99% of the administered dose exhaled unchanged.^[27]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe MAC in humans is 1.04 ± 0.10 atm absolute^[12]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveAt 1.55 atm (hyperbaric conditions), it produces muscle rigidity, laboured breathing, and diaphoresis.^[12]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

neuroscience12 claims12inconclusive

inconclusiveThe discovery of SK2 channel inhibition as an NMDA-independent antidepressant mechanism suggests a dual-mechanism model in which N₂O produces antidepressant effects through at least two convergent pathways: (1) NMDA-dependent glutamatergic disinhibition and (2) SK2-dependent Layer 5 cortical activation^[25]90%

Inconclusive

Abstract not available; SK2/L5 mechanism and NMDA independence are within scope but the dual-pathway synthesis cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveN₂O activates these neurons via SK2 potassium channel inhibition, rescuing stress-induced hypoactivity in this population^[25]90%

Inconclusive

Abstract not available; SK2 channel inhibition and L5 activation are within scope but 'rescuing stress-induced hypoactivity' cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveIzumi and colleagues demonstrated that N₂O produces ketamine-like enhancement of excitatory glutamate transmission in the hippocampus^[26]90%

Inconclusive

Abstract not available; ketamine-like hippocampal glutamate effects are within scope but cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThis mechanism operates in parallel with, and independently of, the supraspinal opioid (dynorphin/KOR) pathway — a dual analgesic architecture that has no direct parallel among other dissociatives.^[28]90%

Inconclusive

Abstract not available; dual analgesic mechanism is within scope but 'no direct parallel among other dissociatives' extends beyond what this citation can verify.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveN₂O activates these neurons via SK2 potassium channel inhibition, rescuing stress-induced hypoactivity in this population^[25]95%

Inconclusive

Abstract not available; cannot verify the SK2 inhibition and stress-rescue mechanism against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveIzumi and colleagues demonstrated that N₂O produces ketamine-like enhancement of excitatory glutamate transmission in the hippocampus^[26]95%

Inconclusive

Abstract not available; cannot verify the hippocampal glutamate enhancement findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThis mechanism operates in parallel with, and independently of, the supraspinal opioid (dynorphin/kappa-opioid-receptor) pathway — a dual analgesic architecture that has no direct parallel among other dissociatives.^[28]95%

Inconclusive

Abstract not available; cannot verify the parallel/independent analgesic architecture claim against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the dual-mechanism antidepressant model against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveN₂O activates these neurons via SK2 potassium channel inhibition, rescuing stress-induced hypoactivity in this population^[25]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveIzumi and colleagues demonstrated that N₂O produces ketamine-like enhancement of excitatory glutamate transmission in the hippocampus^[26]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

receptor pharmacology12 claims12inconclusive

inconclusiveIts binding site is mechanistically distinct from other anaesthetics: site-directed mutagenesis of transmembrane segments TM3 (NR1 F639A) and TM4 (NR2A A825W) — mutations that abolish the inhibitory effects of isoflurane, xenon, and cyclopropane — leave N₂O's NMDA inhibition intact^[2]90%

Inconclusive

Abstract not available; TM3/TM4 mutation finding is within scope but specific residues and full anaesthetic list cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe C. elegans genetic deletion of NMDA receptor subunit NMR-1 abolishes N₂O behavioural effects, confirming target engagement in vivo.^[20]90%

Inconclusive

Abstract not available; in vivo genetic NMDA proof is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe functional output is mediated primarily through kappa opioid receptors (dynorphin), not mu opioid receptors — a distinction with important pharmacological implications, as KOR activation produces analgesia without the respiratory depression characteristic of mu agonists.^[3]90%

Inconclusive

Abstract not available; dynorphin/KOR mediation is within scope but the respiratory depression comparison cannot be verified from this citation.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveInhibition of SK2 channels in Layer 5 pyramidal neurons of the cingulate cortex produces neuronal activation that is both necessary and sufficient for antidepressant-like effects, operating independently of NMDA receptor antagonism.^[25]90%

Inconclusive

Abstract not available; SK2/L5 mechanism and NMDA independence are within scope but 'cingulate cortex' vs 'prefrontal' discrepancy and 'necessary and sufficient' claim cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

Inconclusive

Abstract not available; cannot verify the specific mutagenesis data against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe C. elegans genetic deletion of NMDA receptor subunit NMR-1 abolishes N₂O behavioural effects, confirming target engagement in vivo.^[20]95%

Inconclusive

Abstract not available; cannot verify the NMR-1 deletion findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe functional output is mediated primarily through kappa opioid receptors (dynorphin), not mu opioid receptors — a distinction with important pharmacological implications, as kappa-opioid-receptor activation produces analgesia without the respiratory depression characteristic of mu agonists.^[3]95%

Inconclusive

Abstract not available; cannot verify the kappa vs mu opioid receptor distinction against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the SK2 necessity/sufficiency claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe C. elegans genetic deletion of NMDA receptor subunit NMR-1 abolishes N₂O behavioural effects, confirming target engagement in vivo.^[20]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe functional output is mediated primarily through kappa opioid receptors (dynorphin), not mu opioid receptors — a distinction with important pharmacological implications, as kappa-opioid-receptor activation produces analgesia without the respiratory depression characteristic of mu agonists.^[3]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

pharmacokinetic detail9 claims9inconclusive

inconclusiveThe 'second gas effect' — whereby N₂O's rapid uptake from the alveoli concentrates co-administered gases — has been demonstrated to hasten recovery from co-administered anaesthetics.^[31]90%

Inconclusive

Abstract not available; second gas effect/rapid offset is within stated scope but cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveIn clinical settings, supplemental oxygen is administered for 2–5 minutes after N₂O cessation to prevent hypoxaemia.^[1]90%

Inconclusive

Abstract not available; clinical practice details likely within scope but cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveConsequently, exposure assessment in clinical toxicology relies on indirect biomarkers reflecting the metabolic consequences of cobalamin inactivation: elevated homocysteine (>15 μmol/L in 90.3% of symptomatic cases), elevated methylmalonic acid (>0.4 μmol/L in 93.8%), and depressed methionine levels^[9]90%

Inconclusive

Abstract not available; specific biomarker thresholds and percentages may be in full text but cannot be confirmed from abstract alone.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe "second gas effect" — whereby N₂O's rapid uptake from the alveoli concentrates co-administered gases — has been demonstrated to hasten recovery from co-administered anaesthetics.^[31]95%

Inconclusive

Abstract not available; cannot verify the second gas effect recovery findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveIn clinical settings, supplemental oxygen is administered for 2–5 minutes after N₂O cessation to prevent hypoxaemia.^[1]95%

Inconclusive

Abstract not available; cannot verify the 2–5 minute supplemental oxygen clinical protocol against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the specific biomarker percentage figures against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveIn clinical settings, supplemental oxygen is administered for 2–5 minutes after N₂O cessation to prevent hypoxaemia.^[1]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

safety90 claims90inconclusive

inconclusiveChronic occupational exposure in unscavenged operating rooms is teratogenic in rats at concentrations ≥1,000 ppm^[46]90%

Inconclusive

Abstract not available; teratogenicity at ≥1000 ppm is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveScavenging systems and workplace exposure limits are recommended to protect healthcare workers.^[1]90%

Inconclusive

Abstract not available; occupational safety is likely within scope but cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveGarakani described N₂O abuse-induced psychosis with delirium in the context of concurrent B₁₂ deficiency and anaemia^[47]90%

Inconclusive

Abstract not available; psychosis and B12 deficiency case is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveHowever, the ENIGMA-II trial (n = 7,112) found no increase in cardiovascular mortality or major cardiovascular events at one year in surgical patients exposed to N₂O versus nitrogen-based anaesthesia.^[18]90%

Inconclusive

Abstract not available; no cardiovascular mortality difference at 1 year is within scope but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveDeaths have been attributed to positional asphyxia (e.g., head inside a bag or fixed to a delivery source) or falls following syncope.^[39]90%

Inconclusive

Abstract not available; epidemiology scope covers harm but specific causes of death cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveIn clinical settings, supplemental oxygen for 2–5 minutes post-cessation is standard practice.^[1]90%

Inconclusive

Abstract not available; clinical practice details likely within scope but cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveAt hyperbaric concentrations (1.55 atm), N₂O produces muscle rigidity, laboured breathing, and diaphoresis^[12]90%

Inconclusive

Abstract not available; muscle rigidity at 1.55 atm is within scope but full symptom list cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveN₂O irreversibly oxidises the cobalt ion in cobalamin (vitamin B₁₂) from Co⁺ to Co²⁺/Co³⁺, rendering it non-functional as a cofactor for two critical enzymes:^[40]90%

Inconclusive

Abstract not available; cobalamin oxidation pathway is within scope but oxidation state details cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveSerum B₁₂ levels may remain within the normal range in patients with clinically significant myelopathy^[10]90%

Inconclusive

Abstract not available; case report scope covers B12/SCD but specific normal-serum-B12-with-myelopathy finding cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe most comprehensive toxicity data come from Oussalah and colleagues' systematic review and individual patient data meta-analysis (n = 100):^[9]90%

Inconclusive

Abstract not available; n=100 and toxicity focus are within scope but author name and 'most comprehensive' framing cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe characteristic MRI finding is an inverted 'V-sign' or 'rabbit ear' sign on axial cervical MRI.^[41]90%

Inconclusive

Abstract not available; inverted V-sign MRI finding is within scope but 'rabbit ear' synonym cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveTani and colleagues demonstrated that N₂O abuse causes unique axonal dysfunction distinct from pure B₁₂ deficiency: nerve excitability testing reveals prominent motor superexcitability changes not observed in B₁₂-deficient patients without N₂O exposure, suggesting direct axonal toxicity beyond the metabolic pathway.^[42]90%

Inconclusive

Abstract not available; motor axon dysfunction distinct from B12 deficiency is within scope but 'superexcitability' finding cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveTemple and Horowitz documented subacute combined degeneration occurring despite patient-initiated B₁₂ supplementation. Cessation of use is required.^[43]90%

Inconclusive

Abstract not available; scope directly describes SCD despite self-administered B12 but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveIrreversible nerve damage can occur with prolonged heavy use.^[8]90%

Inconclusive

Abstract not available; neurotoxicity mechanisms are within scope but irreversibility cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveAmess and colleagues first demonstrated this in surgical patients in 1978^[44]90%

Inconclusive

Abstract not available; megaloblastic changes after N2O exposure are within scope but year (1978) and 'first demonstrated' claim cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveO'Sullivan and colleagues established the dose-time relationship: exposure under 6 hours produces no haematological abnormality; 12–24 hours of continuous exposure causes megaloblastic changes that reverse within 12 hours of cessation; folinic acid prophylaxis is protective^[45]90%

Inconclusive

Abstract not available; scope directly lists these dose-time thresholds but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveIn critically ill ICU patients, Amos and colleagues found 16 of 18 patients with megaloblastic changes died, though this high mortality reflected the severity of the underlying conditions rather than N₂O toxicity alone.^[53]90%

Inconclusive

Abstract not available; 16/18 mortality figure is within scope but qualifying attribution to underlying conditions cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveElevated homocysteine resulting from methionine synthase inhibition is a recognised risk factor for thrombotic events^[27]90%

Inconclusive

Abstract not available; metabolic toxicity coverage is within scope but thrombosis risk link cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveKim and colleagues proposed a mechanistic pathway linking N₂O abuse to psychosis: hyperhomocysteinaemia → NMDA receptor downregulation → psychotic symptoms — a 'double-sidedness' in which the same metabolic disruption that impairs myelin also alters excitatory neurotransmission^[48]90%

Inconclusive

Abstract not available; hyperhomocysteinemia-linked psychosis is within scope but mechanistic detail cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusivePsychological dependence liability is also rated low, though cases of compulsive use with heavy daily frequency (>10 sessions per day) have been documented in case reports.^[8]90%

Inconclusive

Abstract not available; dependence liability is within scope but '>10 sessions/day' threshold cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveDiesing and Neu conducted a narrative review of N₂O dependence risk using ICD-10 criteria^[49]90%

Inconclusive

Abstract not available; scope directly confirms ICD-10 dependence review but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveBrunt and colleagues identified 'several lines of evidence' for dependence liability, noting two candidate reinforcement mechanisms: (1) endogenous opioid release providing direct positive reinforcement, and (2) dopamine disinhibition via NMDA antagonism of GABAergic interneurons in mesolimbic pathways, analogous to the mechanism proposed for ketamine and PCP.^[8]90%

Inconclusive

Abstract not available; opioid release and dopamine disinhibition mechanisms are within scope but quoted phrase and authorship cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveSurvey data from Ehirim and colleagues found that some recreational users reported >20 occasions of past-year use, with a minority exhibiting patterns consistent with problematic use.^[50]90%

Inconclusive

Abstract not available; UK recreational use survey is within scope but '>20 occasions' threshold cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveN₂O is routinely co-administered with opioids in clinical anaesthesia, where additive analgesic and anaesthetic effects are well-documented — N₂O reduces the MAC and dose requirements of co-administered opioids, and vice versa^[23]90%

Inconclusive

Abstract not available; mechanistic overview likely covers MAC-sparing effects but cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusivePre-existing cobalamin depletion dramatically accelerates the onset of subacute combined degeneration upon N₂O exposure.^[1]90%

Inconclusive

Abstract not available; B12 concerns are within stated scope but specific acceleration claim cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusivePre-existing cobalamin depletion dramatically accelerates the onset of subacute combined degeneration upon N₂O exposure.^[51]90%

Inconclusive

Abstract not available; B12 deficiency is a stated contraindication but specific acceleration claim cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveN₂O's low blood solubility causes it to diffuse into gas-containing spaces approximately 34 times faster than nitrogen diffuses out, dangerously expanding cavity pressure or volume.^[14]85%

Inconclusive

Abstract available but too brief to verify this claim: states only that N2O is the longest-serving anaesthetic and remains controversial. Does not address gas-space diffusion or the '34 times' figure.

Nitrous oxide is the longest serving member of the anesthesiologist's pharmacologic armamentarium but remains a source of controversy because of fears over its adverse effects.

checked by claude-sonnet-4-6 · Apr 26, 2026

Inconclusive

Abstract not available; closed gas space contraindications are within stated scope but '34 times faster' figure cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveFirst trimester of pregnancy is a relative contraindication based on animal teratogenicity data at prolonged exposures; clinical caution is advised.^[46]90%

Inconclusive

Abstract not available; teratogenicity concerns are within scope but 'first trimester' and 'relative contraindication' framing cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveFirst trimester of pregnancy is a relative contraindication based on animal teratogenicity data at prolonged exposures; clinical caution is advised.^[51]90%

Inconclusive

Abstract not available; pregnancy contraindication is within stated scope but 'first trimester' and 'relative' qualifier cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveGarakani described N₂O abuse-induced psychosis with delirium in the context of concurrent B₁₂ deficiency and anaemia^[47]95%

Inconclusive

Abstract not available; cannot verify the psychosis/delirium case description against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveDeaths have been attributed to positional asphyxia (e.g., head inside a bag or fixed to a delivery source) or falls following syncope.^[39]95%

Inconclusive

Abstract not available; cannot verify the death mechanism attributions against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveIn clinical settings, supplemental oxygen for 2–5 minutes post-cessation is standard practice.^[1]95%

Inconclusive

Abstract not available; cannot verify the 2–5 minute supplemental oxygen standard against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveAt hyperbaric concentrations (1.55 atm), N₂O produces muscle rigidity, laboured breathing, and diaphoresis^[12]95%

Inconclusive

Abstract not available; cannot verify the hyperbaric symptom profile against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveN₂O irreversibly oxidises the cobalt ion in cobalamin (vitamin B₁₂) from Co⁺ to Co²⁺/Co³⁺, rendering it non-functional as a cofactor for two critical enzymes:^[40]95%

Inconclusive

Abstract not available; cannot verify the cobalamin oxidation mechanism against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveSerum B₁₂ levels may remain within the normal range in patients with clinically significant myelopathy^[10]95%

Inconclusive

Abstract not available; cannot verify the normal-range B₁₂ in myelopathy claim against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe most comprehensive toxicity data come from Oussalah and colleagues' systematic review and individual patient data meta-analysis (n = 100):^[9]95%

Inconclusive

Abstract not available; cannot verify the n=100 meta-analysis characterisation against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe characteristic MRI finding is an inverted "V-sign" or "rabbit ear" sign on axial cervical MRI.^[41]95%

Inconclusive

Abstract not available; cannot verify the MRI sign characterisation against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the axonal dysfunction findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveTemple and Horowitz documented subacute combined degeneration occurring despite patient-initiated B₁₂ supplementation. Cessation of use is required.^[43]95%

Inconclusive

Abstract not available; cannot verify the B₁₂ supplementation failure case findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveIrreversible nerve damage can occur with prolonged heavy use.^[8]95%

Inconclusive

Abstract not available; cannot verify the irreversible nerve damage claim against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveAmess and colleagues first demonstrated this in surgical patients in 1978^[44]95%

Inconclusive

Abstract not available; cannot verify the 1978 surgical patient findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the dose-time relationship figures against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the 16/18 ICU mortality figure against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveElevated homocysteine resulting from methionine synthase inhibition is a recognised risk factor for thrombotic events^[27]95%

Inconclusive

Abstract not available; cannot verify the homocysteine-thrombosis link against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the ENIGMA-II cardiovascular findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveChronic occupational exposure in unscavenged operating rooms is teratogenic in rats at concentrations ≥1,000 ppm^[46]95%

Inconclusive

Abstract not available; cannot verify the rat teratogenicity concentration threshold against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveScavenging systems and workplace exposure limits are recommended to protect healthcare workers.^[1]95%

Inconclusive

Abstract not available; cannot verify the occupational protection recommendations against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveKim and colleagues proposed a mechanistic pathway linking N₂O abuse to psychosis: hyperhomocysteinaemia → nmda-receptor downregulation → psychotic symptoms — a "double-sidedness" in which the same metabolic disruption that impairs myelin also alters excitatory neurotransmission^[48]95%

Inconclusive

Abstract not available; cannot verify the hyperhomocysteinaemia→NMDA→psychosis pathway against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveNo formal withdrawal has been characterised for N₂O. Psychological dependence liability is also rated low, though cases of compulsive use with heavy daily frequency (>10 sessions per day) have been documented in case reports.^[8]95%

Inconclusive

Abstract not available; cannot verify the withdrawal characterisation and compulsive use figures against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveDiesing and Neu conducted a narrative review of N₂O dependence risk using ICD-10 criteria^[49]95%

Inconclusive

Abstract not available; cannot verify the ICD-10 dependence review findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveBrunt and colleagues identified "several lines of evidence" for abuse-liability, noting two candidate reinforcement mechanisms: (1) endogenous opioid release providing direct positive reinforcement, and (2) dopamine disinhibition via NMDA antagonism of GABAergic interneurons in mesolimbic pathways, analogous to the mechanism proposed for ketamine and pcp.^[8]95%

Inconclusive

Abstract not available; cannot verify the abuse-liability reinforcement mechanisms against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the survey usage frequency findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the MAC-sparing interaction claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusivePre-existing cobalamin depletion dramatically accelerates the onset of subacute combined degeneration upon N₂O exposure.^[1]95%

Inconclusive

Abstract not available; cannot verify the cobalamin depletion acceleration claim against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusivePre-existing cobalamin depletion dramatically accelerates the onset of subacute combined degeneration upon N₂O exposure.^[51]95%

Inconclusive

Abstract not available; cannot verify the cobalamin depletion acceleration claim against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract available but consists of a single generic sentence confirming the paper covers N₂O mechanisms and adverse effects — insufficient to verify the specific '34 times faster' diffusion ratio cited in the claim.

Nitrous oxide is the longest serving member of the anesthesiologist's pharmacologic armamentarium but remains a source of controversy because of fears over its adverse effects.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the specific 34× diffusion ratio against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveFirst trimester of pregnancy is a relative contraindication based on animal teratogenicity data at prolonged exposures; clinical caution is advised.^[46]95%

Inconclusive

Abstract not available; cannot verify the first-trimester contraindication basis against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveFirst trimester of pregnancy is a relative contraindication based on animal teratogenicity data at prolonged exposures; clinical caution is advised.^[51]95%

Inconclusive

Abstract not available; cannot verify the first-trimester contraindication claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveGarakani described N₂O abuse-induced psychosis with delirium in the context of concurrent B₁₂ deficiency and anaemia^[47]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveDeaths have been attributed to positional asphyxia (e.g., head inside a bag or fixed to a delivery source) or falls following syncope.^[39]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveIn clinical settings, supplemental oxygen for 2–5 minutes post-cessation is standard practice.^[1]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveAt hyperbaric concentrations (1.55 atm), N₂O produces muscle rigidity, laboured breathing, and diaphoresis^[12]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveN₂O irreversibly oxidises the cobalt ion in cobalamin (vitamin B₁₂) from Co⁺ to Co²⁺/Co³⁺, rendering it non-functional as a cofactor for two critical enzymes:^[40]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveSerum B₁₂ levels may remain within the normal range in patients with clinically significant myelopathy^[10]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe most comprehensive toxicity data come from Oussalah and colleagues' systematic review and individual patient data meta-analysis (n = 100):^[9]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe characteristic MRI finding is an inverted "V-sign" or "rabbit ear" sign on axial cervical MRI.^[41]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveTemple and Horowitz documented subacute combined degeneration occurring despite patient-initiated B₁₂ supplementation. Cessation of use is required.^[43]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveIrreversible nerve damage can occur with prolonged heavy use.^[8]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveAmess and colleagues first demonstrated this in surgical patients in 1978^[44]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveElevated homocysteine resulting from methionine synthase inhibition is a recognised risk factor for thrombotic events^[27]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveChronic occupational exposure in unscavenged operating rooms is teratogenic in rats at concentrations ≥1,000 ppm^[46]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveDiesing and Neu conducted a narrative review of N₂O dependence risk using ICD-10 criteria^[49]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusivePre-existing cobalamin depletion dramatically accelerates the onset of subacute combined degeneration upon N₂O exposure.^[1]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusivePre-existing cobalamin depletion dramatically accelerates the onset of subacute combined degeneration upon N₂O exposure.^[51]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract only states N₂O is the 'longest serving' anaesthetic and is 'controversial because of fears over its adverse effects' — no detail on the specific diffusion/expansion claim.

Nitrous oxide is the longest serving member of the anesthesiologist's pharmacologic armamentarium but remains a source of controversy because of fears over its adverse effects.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveFirst trimester of pregnancy is a relative contraindication based on animal teratogenicity data at prolonged exposures; clinical caution is advised.^[46]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveFirst trimester of pregnancy is a relative contraindication based on animal teratogenicity data at prolonged exposures; clinical caution is advised.^[51]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveScavenging systems and workplace exposure limits are recommended to protect healthcare workers.^[1]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

clinical evidence18 claims18inconclusive

inconclusiveThis was the first demonstration that a single sub-anaesthetic N₂O exposure could produce rapid antidepressant effects, analogous to those observed with intravenous ketamine.^[15]90%

Inconclusive

Abstract not available; proof-of-concept RCT scope is directly relevant but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveYan and colleagues conducted an independent RCT in China (2022), demonstrating rapid antidepressant effects of 50% N₂O at 2-hour and 24-hour timepoints with no serious adverse events^[33]90%

Inconclusive

Abstract not available; scope directly confirms rapid effect and no serious adverse events but text cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveLiu and colleagues demonstrated N₂O-associated improvements in executive function in TRD patients.^[35]90%

Inconclusive

Abstract not available; executive function improvement in TRD is within stated scope but cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveGill and colleagues published the most comprehensive synthesis to date in 2025: a systematic review and meta-analysis consolidating all published N₂O antidepressant trials.^[7]90%

Inconclusive

Abstract not available; 2025 systematic review is within scope but author name 'Gill' and 'most comprehensive' framing cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveBessière and colleagues demonstrated in a preclinical model that a single N₂O exposure produces persistent anti-hyperalgesic effects independent of the acute opioid-mediated analgesic mechanism, suggesting a separate long-term pain pathway involving neuroplastic changes^[37]90%

Inconclusive

Abstract not available; persistent anti-hyperalgesic effects independent of opioid mechanism are within scope but cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe primary endpoint — a composite of death and cardiovascular complications — showed no significant difference between N₂O and nitrogen-based anaesthesia^[17]90%

Inconclusive

Abstract not available; no cardiovascular difference is within scope but specific primary endpoint definition cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

Inconclusive

Abstract not available; cannot verify the Chinese RCT findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThis was the first demonstration that a single sub-anaesthetic N₂O exposure could produce rapid antidepressant effects, analogous to those observed with intravenous ketamine.^[15]95%

Inconclusive

Abstract not available; cannot verify the first-demonstration claim or ketamine analogy against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveLiu and colleagues demonstrated N₂O-associated improvements in executive function in TRD patients.^[35]95%

Inconclusive

Abstract not available; cannot verify the executive function improvement findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveGill and colleagues published the most comprehensive synthesis to date in 2025: a systematic review and meta-analysis consolidating all published N₂O antidepressant trials.^[7]95%

Inconclusive

Abstract not available; cannot verify the 2025 systematic review scope claims against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify the persistent anti-hyperalgesic preclinical findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe primary endpoint — a composite of death and cardiovascular complications — showed no significant difference between N₂O and nitrogen-based anaesthesia^[17]95%

Inconclusive

Abstract not available; cannot verify the ENIGMA-II primary endpoint findings against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThis was the first demonstration that a single sub-anaesthetic N₂O exposure could produce rapid antidepressant effects, analogous to those observed with intravenous ketamine.^[15]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveLiu and colleagues demonstrated N₂O-associated improvements in executive function in TRD patients.^[35]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveGill and colleagues published the most comprehensive synthesis to date in 2025: a systematic review and meta-analysis consolidating all published N₂O antidepressant trials.^[7]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveThe primary endpoint — a composite of death and cardiovascular complications — showed no significant difference between N₂O and nitrogen-based anaesthesia^[17]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

comparative pharmacology15 claims15inconclusive

inconclusiveThis extreme brevity is a direct consequence of its low blood:gas partition coefficient (~0.47) and the absence of hepatic metabolism — there is no metabolic half-life to prolong effects beyond the period of active inhalation.^[1]90%

Inconclusive

Abstract not available; partition coefficient and absence of hepatic metabolism likely within scope but cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveStructural studies confirm that N₂O binds hydrophobic flexible cavities distinct from the ethanol/ketamine pocket^[21]90%

Inconclusive

Abstract not available; structural binding data is within scope but cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveWhile ketamine analgesia is attributed primarily to direct NMDA receptor blockade in spinal and supraspinal pain circuits, N₂O recruits a dual pathway: endogenous opioid (dynorphin/KOR) release supraspinally and noradrenergic (alpha₂B) activation spinally^[4]90%

Inconclusive

Abstract not available; mu-opioid independence/KOR implication is within scope but full dual pathway comparison with ketamine cannot be verified from this citation alone.

checked by claude-sonnet-4-6 · Apr 26, 2026

Inconclusive

Abstract not available; dual supraspinal opioid + spinal alpha2 mechanism is within scope but full comparative claim cannot be verified.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveHowever, N₂O's antidepressant mechanism additionally involves SK2 channel inhibition in Layer 5 prefrontal cortex — a pathway independent of NMDA receptor function^[25]90%

Inconclusive

Abstract not available; SK2/L5 prefrontal mechanism and NMDA independence are within scope but cannot be confirmed.

checked by claude-sonnet-4-6 · Apr 26, 2026

Inconclusive

Abstract not available; cannot verify the absence of hepatic metabolism claim against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveStructural studies confirm that N₂O binds hydrophobic flexible cavities distinct from the ethanol/ketamine pocket^[21]95%

Inconclusive

Abstract not available; cannot verify the binding site structural distinction against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveWhile ketamine analgesia is attributed primarily to direct NMDA receptor blockade in spinal and supraspinal pain circuits, N₂O recruits a dual pathway: endogenous opioid (dynorphin/kappa-opioid-receptor) release supraspinally and noradrenergic (alpha₂B) activation spinally^[4]95%

Inconclusive

Abstract not available; cannot verify the dual pathway comparison with ketamine against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveWhile ketamine analgesia is attributed primarily to direct NMDA receptor blockade in spinal and supraspinal pain circuits, N₂O recruits a dual pathway: endogenous opioid (dynorphin/kappa-opioid-receptor) release supraspinally and noradrenergic (alpha₂B) activation spinally^[28]95%

Inconclusive

Abstract not available; cannot verify the supraspinal opioid/spinal alpha₂ dual pathway against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveHowever, N₂O's antidepressant mechanism additionally involves SK2 channel inhibition in Layer 5 prefrontal-cortex — a pathway independent of NMDA receptor function^[25]95%

Inconclusive

Abstract not available; cannot verify the SK2/NMDA independence claim against the source.

checked by claude-sonnet-4-6 · Jul 18, 2026

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveStructural studies confirm that N₂O binds hydrophobic flexible cavities distinct from the ethanol/ketamine pocket^[21]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveWhile ketamine analgesia is attributed primarily to direct NMDA receptor blockade in spinal and supraspinal pain circuits, N₂O recruits a dual pathway: endogenous opioid (dynorphin/kappa-opioid-receptor) release supraspinally and noradrenergic (alpha₂B) activation spinally^[4]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveWhile ketamine analgesia is attributed primarily to direct NMDA receptor blockade in spinal and supraspinal pain circuits, N₂O recruits a dual pathway: endogenous opioid (dynorphin/kappa-opioid-receptor) release supraspinally and noradrenergic (alpha₂B) activation spinally^[28]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

inconclusiveHowever, N₂O's antidepressant mechanism additionally involves SK2 channel inhibition in Layer 5 prefrontal-cortex — a pathway independent of NMDA receptor function^[25]100%

Inconclusive

Abstract not available; cannot verify claim.

checked by claude-sonnet-4-6 · Jul 18, 2026

Coverage & Gaps

effect links

74 links · 74 approved · 29 audited0/74 with evidence basis

interactions

24 approved pairs0/24 graded

Research Trail

substance-article pipeline-v5 Apr 26, 2026

Step	Source	Query	Results
1database lookup	PubChem	nitrous oxide	1 result, 1 selected
selection rationaleselection rationale Primary chemical identity source
2literature search	PubMed	nitrous oxide pharmacology mechanism NMDA receptor anesthesia	12 results, 7 selected
selection rationaleselection rationale Core pharmacology and mechanism papers
3literature search	PubMed	nitrous oxide opioid system endogenous opioid analgesic	10 results, 5 selected
selection rationaleselection rationale Opioid mechanism data essential for pharmacology section
4literature search	PubMed	nitrous oxide antidepressant treatment-resistant depression clinical trial	10 results, 6 selected
selection rationaleselection rationale Clinical trial data for antidepressant effects
5literature search	PubMed	nitrous oxide toxicity adverse effects vitamin B12 myelopathy subacute combined degeneration	10 results, 8 selected
selection rationaleselection rationale Critical safety/toxicity data
6literature search	OpenAlex	nitrous oxide N2O recreational abuse neurotoxicity	10 results, 7 selected
selection rationaleselection rationale Landmark papers on recreational use and neurotoxicity
7clinical trial search	ClinicalTrials.gov	nitrous oxide depression anxiety treatment	10 results, 5 selected
selection rationaleselection rationale Active and completed trials directly relevant to therapeutic use
8literature search	PubMed	nitrous oxide methionine synthase cobalamin vitamin B12 mechanism inactivation	3 results, 2 selected
selection rationaleselection rationale Metabolic mechanism of toxicity
9literature search	PubMed	nitrous oxide history neuropsychiatry	1 result, 1 selected
selection rationaleselection rationale Primary historical reference
10literature search	PubMed	ENIGMA trial nitrous oxide anesthesia Myles	8 results, 3 selected
selection rationaleselection rationale Large-scale clinical safety data
11literature search	OpenAlex	Nagele nitrous oxide antidepressant treatment resistant depression 2015	5 results, 1 selected
selection rationaleselection rationale Original proof-of-concept antidepressant trial, most-cited N2O psychiatric paper
12legal status search	WebSearch/UK Gov	nitrous oxide legal status UK Psychoactive Substances Act 2023 scheduling US DEA Australia	10 results, 2 selected
selection rationaleselection rationale Legal status for multiple jurisdictions
13literature search	PubMed	nitrous oxide bone marrow hematopoiesis megaloblastic anemia	4 results, 3 selected
selection rationaleselection rationale Classic hematopoietic toxicity papers
14literature search	PubMed	nitrous oxide minimum alveolar concentration MAC potency anesthetic dose	5 results, 1 selected
selection rationaleselection rationale Key potency data - establishes N2O is subpotent as sole anesthetic at 1 atm
15literature search	PubMed	nitrous oxide antinociception noradrenergic spinal cord alpha-2 adrenergic	3 results, 2 selected
selection rationaleselection rationale Key papers establishing noradrenergic descending pathway as analgesic mechanism
16literature search	PubMed	nitrous oxide nausea vomiting postoperative ENIGMA adverse effect	6 results, 2 selected
selection rationaleselection rationale PONV as key adverse effect of clinical N2O use
17document retrieval	OpenAlex	Brunt 2022 neurotoxicity abuse liability narrative review N2O	1 result, 1 selected
selection rationaleselection rationale Best review on abuse liability mechanisms
18legal status search	WebSearch	nitrous oxide legal status Australia Canada EU 2023 2024	10 results, 2 selected
selection rationaleselection rationale Comprehensive legal status across jurisdictions
19document retrieval	PubMed	Past present future nitrous oxide Lew McKay Maze 2018	1 result, 1 selected
selection rationaleselection rationale Comprehensive modern review covering contraindications, physical properties, clinical use
20document retrieval	PubMed	Palanca 2023 persistent brain connectivity nitrous oxide	1 result, 1 selected
selection rationaleselection rationale Neural correlates of persistent N2O effects relevant to antidepressant mechanism
21cross reference	cross_reference	Verify chemical identity: PubChem CID 948 vs brief seed data	1 result, 0 selected
selection rationaleselection rationale Chemical identity verification completed
22cross reference	cross_reference	Verify interactions listed as unknown in brief - opioids, alcohol, GHB	0 results, 0 selected
selection rationaleselection rationale Interaction status confirmed as largely unknown for listed substances

Research document (raw, unedited pipeline output)

# Research Output: Nitrous Oxide (N₂O)
**PSX ID:** PSX-0278 | **Slug:** nitrous | **Generation Provenance:** ca3cf04c-4d94-409c-a841-83479ee5e338

---

## Chemical Identity

PubChem lookup (CID 948) confirmed all chemical identity data [Ref 1 — see note: PubChem is cited as an unnamed reference throughout; all chemical data verified against CID 948].

| Property | Value |
|---|---|
| PubChem CID | 948 |
| Molecular formula | N₂O |
| Molecular weight | 44.013 g/mol |
| IUPAC name | nitrous oxide |
| InChIKey | GQPLMRYTRLFLPF-UHFFFAOYSA-N |
| SMILES | [N-]=[N+]=O |
| CAS number | 10024-97-2 |

**Physical properties:** Colorless, slightly sweet-smelling gas at room temperature and standard pressure. Non-flammable. Blood:gas partition coefficient ≈ 0.47 — one of the lowest among inhaled anesthetics — which accounts for its extremely rapid onset and offset (Lew et al. 2018 [Ref 52]). Stored as a liquid under pressure in cartridges/cylinders (liquefaction at room temperature requires ~50 bar). Boiling point: −88.48°C. Critical temperature: 36.4°C.

**Discrepancies with seed data:** The brief contained no SMILES, no PubChem CID, no InChIKey, and no molecular formula. All have now been confirmed via PubChem. The pharmacological class listed in the brief ("Opioid system, Ion channel modulator, NMDA receptor antagonist") is substantively accurate but incomplete — see Pharmacology section for fuller characterization.

---

## Pharmacology

### Primary Receptor Targets and Mechanisms

**1. NMDA receptor antagonism (principal mechanism)**
N₂O is a non-competitive antagonist of NMDA (N-methyl-D-aspartate) receptors, acting predominantly as an open-channel blocker. Nagele et al. (2004 [Ref 3]) provided in vivo genetic proof in *C. elegans* that NMDA receptor NMR-1 is required for N₂O's behavioral effects, confirming the receptor target established by electrophysiological studies. Importantly, N₂O's inhibition of NMDA receptors is NOT affected by mutations in transmembrane segments TM3 (NR1 F639A) and TM4 (NR2A A825W) that abolish the effects of most other anesthetics, indicating a mechanistically distinct binding site (Ogata et al. 2006 [Ref 5]). X-ray crystallography demonstrated that N₂O binds to hydrophobic flexible cavities within protein monomers — distinct from the ethanol/ketamine binding pocket (Colloc'h et al. 2007 [Ref 4]).

No specific Ki or IC₅₀ values at the NMDA receptor are available in the published literature for N₂O as a gas (its potency is conventionally expressed as Minimum Alveolar Concentration, or MAC). **FLAG for review:** Unlike typical NMDA antagonists measured in nanomolar binding affinity, N₂O is a gas whose potency is expressed in atmospheric partial pressures. Specific binding constants are absent from the literature.

**2. Opioid system activation (analgesic mechanism)**
N₂O stimulates the release of endogenous opioid peptides in the central nervous system via a nitric oxide (NO)-dependent mechanism. Ohgami et al. (2010 [Ref 8]) demonstrated that 70% N₂O significantly increases dialysate levels of β-endorphin in the arcuate nucleus and periaqueductal gray of rats, and this effect is blocked by the NO synthase inhibitor L-NAME. Branda et al. (2000 [Ref 11]) demonstrated using antisera and peptidase inhibitors that **dynorphin** (not enkephalin or β-endorphin) is the primary endogenous opioid mediating N₂O antinociception in the mouse abdominal constriction test. Koyama et al. (2009 [Ref 10]) showed that mu-opioid receptor knockout mice retain normal N₂O analgesia, implicating the kappa opioid receptor (KOR)/dynorphin system. Guo et al. (1996 [Ref 46]) established a dual mechanism: supraspinal opioid release combined with spinal alpha₂ adrenoceptor activation.

**3. Noradrenergic descending pathway (analgesic mechanism)**
N₂O stimulates noradrenergic neurons in pontine brainstem nuclei (A5, locus coeruleus, A7), increasing norepinephrine release. Sawamura et al. (2000 [Ref 45]) demonstrated in mice using DbetaH-saporin lesioning of noradrenergic nuclei that this pathway is required for N₂O analgesia but NOT for its sedative effects. The specific adrenoceptor mediating analgesia is the **alpha₂B subtype** (not alpha₂A as for exogenous agonists). Emmanouil & Quock (2007 [Ref 2]) note that anxiolysis may involve GABA-A receptor modulation at specific subunits, similar to benzodiazepines, though this mechanism is less well characterized.

**4. Ion channel modulation**
Bessiere et al. (2021 [Ref 12]) summarized additional targets: activation of **TREK-1** (TWIK-related K⁺ channel 1) on first-order neurons reduces neuronal excitability; blockade of **voltage-dependent calcium channels** attenuates neuronal excitability; possible blockade of **voltage-dependent sodium channels**. These contribute to peripheral and central analgesic effects.

**5. SK2 channel inhibition (novel antidepressant mechanism)**
Cichon et al. (2025 [Ref 6]) — the most recent mechanistic paper — demonstrated that N₂O activates Layer 5 (L5) pyramidal neurons in the cingulate cortex via inhibition of **calcium-sensitive SK2 potassium channels**, independent of NMDA receptor function. L5 activation rescues stress-associated hypoactivity and is necessary for antidepressant-like effects in rodents. This suggests N₂O's antidepressant mechanism is more complex than simple NMDA antagonism.

**6. Glutamatergic synaptic effects**
Izumi et al. (2022 [Ref 7]) showed N₂O has ketamine-like effects on excitatory glutamate transmission in the adult hippocampus, enhancing glutamate-mediated synaptic activity consistent with NMDA antagonism disinhibition.

### Pharmacokinetics

- **Route:** Inhaled gas
- **Absorption:** Extremely rapid pulmonary absorption; driven by alveolar partial pressure
- **Blood:gas partition coefficient:** ~0.47 (low; comparable only to xenon among anesthetics); this explains onset within 5-10 seconds and offset within 1-5 minutes (Lew et al. 2018 [Ref 52])
- **Distribution:** Rapid equilibration to all tissues; high CNS penetration
- **Metabolism:** Negligible. N₂O is not metabolized by cytochrome P450 enzymes. It is eliminated essentially unchanged via exhalation (>99% pulmonary elimination) (Gernez et al. 2023 [Ref 25])
- **Elimination:** Pulmonary; clinical recovery typically complete within minutes after cessation
- **MAC in humans:** 1.04 ± 0.10 atm absolute (Hornbein et al. 1982 [Ref 40]). Because MAC exceeds 1 atm, N₂O **cannot achieve full surgical anesthesia at standard atmospheric pressure alone**; at 1.55 atm it produces muscle rigidity, labored breathing, and sweating. This establishes N₂O as a subpotent sole anesthetic at sea level.
- **Diffusion hypoxia:** Upon abrupt cessation, N₂O rapidly diffuses from blood back into alveoli, diluting oxygen and potentially causing transient hypoxia; requires supplemental O₂ for 2-5 min after use (clinical guideline)
- **No CYP enzyme involvement:** No known CYP inhibition or induction; no pharmacokinetic drug interactions via hepatic metabolism

**FLAG:** Published human PK parameters (Tmax, specific plasma concentration data) from recreational-dose studies are absent from the literature. Gernez et al. (2023 [Ref 25]) note N₂O is "very challenging to measure in biological matrices," which is why indirect biomarkers (B12, homocysteine, MMA) are used diagnostically.

---

## History

- **1772:** Joseph Priestley first recorded the synthesis of N₂O (Gillman 2019 [Ref 32]; also referenced in Hu et al. 2023 [Ref — OpenAlex, not separately captured as PMID])
- **Late 1790s–1800:** Humphry Davy extensively experimented with the psychotropic properties of N₂O and published his findings in a landmark book ("Researches, Chemical and Philosophical, Chiefly Concerning Nitrous Oxide") in 1800, including self-experiments and experiments on other researchers and poets (Coleridge, Southey). He noted analgesic properties but did not pursue surgical application (Gillman 2019 [Ref 32])
- **1844:** Horace Wells, a Hartford dentist, discovered N₂O as a surgical anesthetic after witnessing a demonstration. He extracted one of his own molars under N₂O anesthesia and subsequently attempted a public demonstration at Harvard Medical School in 1845, which was considered a failure. He is credited as the first to use N₂O in dentistry (Gillman 2019 [Ref 32])
- **1870s onward:** N₂O became widely used in dentistry (Gillman 2019 [Ref 32])
- **1930s:** N₂O became the mainstay of intrapartum pain relief (Sanders et al. 2008 [Ref 1])
- **1920–1950:** Seminal neuropsychiatric research using anesthetic concentrations of N₂O (Gillman 2019 [Ref 32])
- **1980s:** Low-dose titration technique developed in dentistry for sub-anesthetic psychotropic use; first applied to psychiatric conditions (Gillman 2019 [Ref 32])
- **1994:** Term "Psychotropic Analgesic Nitrous Oxide (PAN)" introduced to distinguish non-anesthetic from anesthetic concentrations (Gillman 2019 [Ref 32])
- **2008:** Sanders, Weimann & Maze published landmark toxicology/mechanism review (Anesthesiology) [Ref 1]
- **2014–2015:** Nagele et al. published the first proof-of-concept RCT showing rapid antidepressant effects of a single 1-hour N₂O inhalation in treatment-resistant major depression (Nagele et al. 2015 [Ref 31])
- **2021:** Phase 2 clinical trial (Science Translational Medicine) confirming antidepressant efficacy at 25% and 50% N₂O [Ref 13]
- **2023 (UK):** N₂O reclassified as Class C drug under Misuse of Drugs Act 1971 [Ref 42]
- **2025:** Systematic review and meta-analysis of N₂O antidepressant efficacy published [Ref 29]

### Regulatory History
- N₂O has been used continuously in medicine since the 1840s — the longest continuously used anesthetic agent
- Environmental concerns (N₂O is a potent greenhouse gas and stratospheric ozone depleter) have prompted efforts to reduce clinical use (Lew et al. 2018 [Ref 52])
- The **ENIGMA trial** (Evaluation of Nitrous oxide In the Gas Mixture for Anaesthesia) was a landmark randomized trial of N₂O in 7,112 at-risk surgical patients (Myles et al. 2014 [Ref 33]); original ENIGMA I reported increased postoperative complications with N₂O; ENIGMA-II found no cardiovascular mortality difference but confirmed significant PONV risk (Myles et al. 2016 [Ref 47]) and raised pulmonary complication concerns (Peyton et al. 2023 [Ref 36 — see note: Peyton 2023 not explicitly added to registry; not cited in output])

---

## Subjective Effects

**From clinical and dental literature:**
The effects of N₂O vary substantially with dose/inhaled concentration (Emmanouil & Quock 2007 [Ref 2]):

- **Sub-anesthetic (10-30%, dental range):** Anxiolysis, mild euphoria, tingling sensations, light-headedness, warmth, mood elevation; patient remains conscious and cooperative
- **Moderate (30-50%, Entonox range for obstetric/ED use):** Pronounced analgesia, dissociation, dizziness, perceptual changes, impaired cognition; may include euphoria and giggling ("laughing gas")
- **Higher concentrations (50-70%, used in research and recreational heavy use):** More pronounced dissociative effects, visual and auditory alterations, depersonalization, derealization, possible amnesia; effects remain brief due to rapid elimination
- **Near-anesthetic (>70%):** Approaches sedation/loss of consciousness; muscle rigidity at >100% (requires hyperbaric conditions, above 1 atm)

**From recreational use survey data:**
Ehirim et al. (2018 [Ref 24]) surveyed 140 young adults in England; 27.9% reported past-year use; typical effect reported as lasting up to 5 minutes, typically 1-10 inhalations per session; predominantly social use setting. The "hippy crack" or "nangs" format (whipped cream charger cartridges, typically 8g N₂O each, inhaled via balloon) produces very brief effects consistent with the DB dose/duration data.

**Brain neuroimaging data:**
Pelentritou et al. (2018 [Ref — see note: PMID 29364232 not explicitly added to registry]) performed MEG/EEG recordings showing dose-dependent effects on auditory evoked responses. Palanca et al. (2023 [Ref 53]) demonstrated persistent increases in global brain connectivity in visual cortex and dorsal attention network lasting >24 hours after a single N₂O inhalation in healthy volunteers — a finding with implications for antidepressant mechanism.

**Duration data verification:**
The brief's duration data (onset 5-10s, come-up 5-10s, peak 15-30s, offset 1-5 min, total 1-5 min) is consistent with published pharmacokinetics (blood:gas partition coefficient ~0.47) and the survey data from Ehirim 2018 [Ref 24]. These values appear accurate.

**Effects taxonomy:**
The listed effects (dizziness, euphoria, tactile sensations, dissociation, geometry, amnesia, cognitive impairment, bodily lightness, anxiety suppression, motor control impairment, time distortion) are consistent with published descriptions from dental, clinical, and survey literature. No controlled human studies using validated psychedelic/dissociative effect rating scales (e.g., CEQ, 5D-ASC, CADSS) at recreational doses were identified.

---

## Safety & Toxicity

### Acute Toxicity
- **LD50 in humans:** Not established. N₂O is not directly cytotoxic at recreational concentrations
- **Primary acute hazard:** Asphyxiation from oxygen displacement. If used without supplemental O₂ (e.g., breathing pure N₂O from a bag), hypoxic loss of consciousness can occur within seconds. Deaths have been reported from positional asphyxia or falls following loss of consciousness
- **Diffusion hypoxia:** Upon abrupt cessation, N₂O diffuses rapidly from blood to alveoli, transiently reducing alveolar O₂; self-resolves with ambient air breathing but clinically managed with supplemental O₂ for 5 min post-use

### Chronic Neurotoxicity: Vitamin B12 Inactivation

The most serious adverse effect of repeated/chronic N₂O use is **subacute combined degeneration (SCD)** of the spinal cord via B12 inactivation (Oussalah et al. 2019 [Ref 15]).

**Mechanism:** N₂O irreversibly oxidizes the cobalt ion (Co+) in cobalamin (vitamin B12) to Co²⁺ or Co³⁺, rendering it incapable of acting as a cofactor for:
1. **Methionine synthase** (methylcobalamin-dependent): inability to convert homocysteine → methionine → SAM (S-adenosylmethionine); impairs myelin synthesis and methylation reactions
2. **Methylmalonyl-CoA mutase** (adenosylcobalamin-dependent): methylmalonyl-CoA cannot be converted to succinyl-CoA; impairs Krebs cycle fueling (Joncquel et al. 2022 [Ref 37])

**Important distinction:** N₂O causes **functional inactivation** of cobalamin rather than true B12 deficiency — serum B12 levels may be **normal** even in patients with clinically significant toxicity (Wang et al. 2024 [Ref 30]). Diagnosis requires homocysteine (elevated), methylmalonic acid/MMA (elevated), and potentially methionine levels.

**Clinical outcomes (Oussalah et al. 2019 meta-analysis [Ref 15], n=100 patients):**
- Subacute combined degeneration: 28%
- Myelopathy: 26%
- Generalized demyelinating polyneuropathy: 23%
- Paresthesia: 80%
- Unsteady gait: 58%
- Weakness: 43%
- T2 spinal cord hyperintensity on MRI: 68% of cases
- At least one hematological abnormality: 71.7%
- Homocysteine >15 μmol/L: 90.3%
- MMA >0.4 μmol/L: 93.8%
- Median patient age: 27 years; 57% recreational users

MRI finding: inverted "V-sign" or "rabbit ear" sign on axial cervical MRI is characteristic (Yuan et al. 2017 [Ref 16]).

Tani et al. (2019 [Ref 27]) demonstrated that N₂O abuse causes **unique axonal dysfunction distinct from pure B12 deficiency** — N₂O patients show prominent motor superexcitability changes not seen in B12-deficient patients, suggesting direct axonal toxicity beyond the metabolic pathway.

**Reversibility:** Depends on severity and duration. Early treatment (cessation + intramuscular/oral B12) usually leads to gradual improvement, but recovery may take months and many patients report residual symptoms. Irreversible nerve damage can occur (Brunt et al. 2022 [Ref 22]).

**B12 supplementation inadequacy:** Temple & Horowitz (2022 [Ref 19]) documented SCD occurring despite patient-initiated B12 supplementation; **cessation of use is required, not supplementation alone**.

### Hematological Toxicity
- Amess et al. (1978 [Ref 38]) and O'Sullivan et al. (1981 [Ref 39]) established that N₂O causes megaloblastic bone marrow changes with **prolonged continuous exposure** (>12-24 hours in ICU/surgical settings)
- O'Sullivan: exposure <6h = no abnormality; 12-24h = megaloblastic changes (reversible within 12h of cessation); folinic acid prophylaxis is protective
- Amos et al. (1982 [Ref 56]) found 16 of 18 ICU patients with megaloblastic changes died (high-risk population; not attributable to N₂O alone)

### Psychiatric Adverse Effects
- Psychosis: case reports of N₂O abuse-induced psychosis and delirium (Garakani 2025 [Ref 21]; Kim et al. 2019 [Ref 41])
- Kim et al. (2019 [Ref 41]) proposed a mechanism: hyperhomocysteinemia → NMDA receptor downregulation → psychotic symptoms (the "double-sidedness" of N₂O's NMDA effects)
- Case described: 37-year-old with agitation, paranoia, hallucinations, anemia after 6 months of increasing recreational use; responded to antipsychotics + benzodiazepine taper + B12

### Cardiovascular Risks
- Elevated homocysteine (from methionine synthase inhibition) → thrombotic events reported (Gernez et al. 2023 [Ref 25])
- ENIGMA-II (n=7,112): no increase in cardiovascular mortality or major cardiovascular events at 1 year compared to N₂-based anesthesia (Leslie et al. 2015 [Ref 34])
- ENIGMA-II: significant increase in severe PONV with N₂O (Myles et al. 2016 [Ref 47])

### Occupational Exposure
- Chronic occupational exposure: teratogenic in rats at ≥1000 ppm (unscavenged operating rooms) (Burm 2003 [Ref 57])
- Clinical guideline: occupational exposure should be limited; scavenging systems recommended (Lew et al. 2018 [Ref 52])

---

## Harm Reduction

### Contraindications (Published)
Based on Sanders et al. 2008 [Ref 1], Huang & Johnson 2016 [Ref 54], Lew et al. 2018 [Ref 52], and Emmanouil & Quock 2007 [Ref 2]:

**Medical contraindications:**
1. **Vitamin B12 deficiency or disorders of B12 metabolism** (pernicious anemia, vegetarian/vegan diet with low B12, malabsorption syndromes) — dramatically increased risk of myelopathy
2. **Closed gas-containing cavities:** Pneumothorax, middle ear disease, bowel obstruction, pneumocranium, air embolism — N₂O's low solubility causes it to diffuse into gas-containing spaces ~34x faster than N₂ diffuses out, expanding cavity pressure or volume dangerously
3. **First trimester of pregnancy** (animal teratogenicity data; clinical caution)
4. **Pre-existing peripheral neuropathy or myelopathy**
5. **Recent ophthalmic surgery** involving intraocular gas (N₂O expands intraocular gas bubbles)

**Recreational harm reduction principles (from Brunt et al. 2022 [Ref 22], van Amsterdam et al. 2022 [Ref 23]):**
- Use balloons to self-titrate dose, **not bags or direct from tank** (asphyxiation risk)
- Use in seated position to avoid falls upon loss of consciousness
- Do not use alone
- Ensure adequate oxygen by breathing normal air between inhalations
- Limit frequency and quantity of use
- Regular B12, homocysteine, and MMA blood testing for heavy/repeated users
- Seek immediate medical attention for neurological symptoms (tingling, weakness, balance problems)
- B12 supplementation does **not** protect against SCD if use continues (Temple & Horowitz 2022 [Ref 19])

**Emergency response:**
- In case of loss of consciousness: ensure airway and supplemental O₂
- Suspected N₂O myelopathy: urgent B12, homocysteine, MMA blood tests + spinal MRI; start high-dose B12 replacement; cease N₂O immediately

---

## Tolerance & Dependence

**Tolerance:**
The seed data states "buildup: develops with prolonged and repeated use; half-life: 5 days; full reset: 1.5 weeks." No specific published human studies directly establishing these precise tolerance timeline parameters were identified. These values appear to be derived from community reports or clinical observation rather than controlled studies. **FLAG for review — these specific tolerance half-life and reset values are not verified in published literature.**

NMDA receptor tolerance (receptor upregulation) has been proposed as a mechanism analogous to ketamine tolerance, but specific N₂O tolerance studies in humans are lacking. The antidepressant studies show persistent effects lasting 1-2 weeks after a single 1-hour session (Nagele et al. 2021 [Ref 13]), which may suggest enduring neurobiological changes beyond simple receptor occupancy.

**Dependence:**
Diesing & Neu (2025 [Ref 49]) conducted a narrative review of N₂O dependence risk using ICD-10 criteria; the paper was published in German (Der Nervenarzt) with limited abstract data available.

Brunt et al. (2022 [Ref 22]) identified "several lines of evidence for N₂O dependence liability" but note the mechanism is controversial. Two candidate mechanisms:
1. **Opioid system interaction** (endogenous opioid release → reinforcement)
2. **Dopamine disinhibition via NMDA antagonism** (N₂O blocks NMDA → reduces GABA inhibition on dopaminergic pathways → increased dopamine release, similar to ketamine/PCP mechanism)

The seed data characterization (physical dependence: low; psychological dependence: low; "mildly addictive with moderate potential for abuse") is consistent with the published literature. Cases of compulsive use with heavy frequency (>10+ sessions per day) have been documented in case reports (Brunt et al. 2022 [Ref 22]).

The Ehirim 2018 survey [Ref 24] noted some users reported >20 occasions of past-year use, with a minority exhibiting patterns consistent with problematic use.

**Cross-tolerance:** No published data on cross-tolerance between N₂O and ketamine, PCP, or other NMDA antagonists at recreational doses.

---

## Interactions

### Overview
The brief lists 20 interactions, all characterized as "unknown." No specific published pharmacokinetic or pharmacodynamic interaction studies for any of the listed opioids or depressants at recreational doses were identified in the literature search.

### Opioids (ALL LISTED: Pethidine, Sufentanil, Buprenorphine, Hydrocodone, Oxycodone, Acetylfentanyl, Codeine, Ethylmorphine, Tapentadol, Heroin, Morphine, O-Desmethyltramadol, Methadone, Dihydrocodeine, U-47700, Hydromorphone, Dextropropoxyphene, Oxymorphone, Tramadol, Fentanyl)
**Status: All unknown (no recreational dose-specific data)**

**What the clinical anesthesia literature shows:** N₂O is routinely co-administered with opioids in clinical anesthesia with well-documented **additive/synergistic** analgesic and anesthetic effects. N₂O reduces the MAC (and dose requirements) of opioids; opioids in turn reduce N₂O MAC requirements. At anesthetic doses, the combination is common practice (Emmanouil & Quock 2007 [Ref 2]).

**Mechanism-based concern for recreational combinations:** Both N₂O (via opioid system activation) and opioids act on opioid receptors. Combined opioidergic effects would theoretically increase CNS depression, respiratory depression, and sedation. However, because N₂O's opioid-system effects are indirect (stimulating endogenous release via NO pathway) and its elimination is extremely rapid, the clinical risk profile may differ from, e.g., combining two opioids. **No dose-response or safety studies exist for recreational N₂O + opioid combinations.**

**FLAG:** All opioid interactions remain "unknown" and carry a theoretical elevated risk of CNS/respiratory depression. Each combination should be flagged for human review before any interaction severity is assigned.

### Depressants: Alcohol, GHB/GBL
**Status: Unknown (no specific studies)**
Both alcohol and GHB/GBL are CNS depressants acting on multiple targets overlapping with N₂O's effects. Combined use would be expected to produce additive CNS depression, increased sedation, and increased hypoxia risk. No published dose-response studies for recreational combinations exist.

**Kratom:** No published interaction data found.

### Important Negative Interactions
- **No serotonergic mechanism:** N₂O does not act on serotonin receptors; serotonin syndrome risk is not established
- **No CYP450 involvement:** No hepatic drug interactions via enzyme inhibition/induction
- **No monoamine oxidase involvement**

---

## Legal Status

### United Kingdom
N₂O was reclassified as a **Class C drug** under the **Misuse of Drugs Act 1971** (Amendment) in **November 2023** [Ref 42]. It is placed in Schedule 5, preserving legitimate medical and dental use. The key restriction: possession or supply with intent for recreational inhalation (defined as "wrongful inhalation" — any inhalation not for a medical or dental purpose) is now illegal. Prior to November 2023, N₂O had limited control under the Psychoactive Substances Act 2016 but was not a controlled substance (UK Home Office Circular 006/2023 [Ref 42]).

### United States
N₂O is **not scheduled under the federal Controlled Substances Act**. It has recognized medical, dental, and food-additive (culinary) uses. Sale of chargers ("whippits") is legal but several states have enacted restrictions on sale to minors or sale with intent to inhale. The FDA regulates N₂O as a food additive. No federal scheduling as of 2026 [Ref 50].

### Australia
Regulation is **state-by-state** and evolving [Ref 50]:
- **Victoria:** Non-therapeutic N₂O classified as Schedule 6 poison
- **South Australia:** Controlled Substances (Poisons) (Nitrous Oxide) Variation Regulations 2019 — age restrictions (no sale to under-18s) and time restrictions (no retail between 10pm–5am)
- **New South Wales:** Government consulting on reform proposals (2024 consultation paper)
- No federal scheduling as of 2025-2026

### European Union
- **France (2023):** Decree limiting sale to individuals to cartridges ≤8.6g in boxes of ≤10
- **EU Commission:** Considering harmonized classification as **Category 1B reproductive toxicant** (2024)
- **Belgium, Netherlands:** Various national restrictions on large-format tanks (1kg/2.2kg cartridges popular for recreational use) [Ref 50]

### Canada
Health Canada has issued recalls of N₂O chargers marketed for inhalation without market authorization. Not federally scheduled [Ref 50].

### Global
N₂O is **not scheduled under UN drug conventions** (Single Convention on Narcotic Drugs 1961, Convention on Psychotropic Substances 1971, or 1988 Convention). This explains the difficulty of controlling its supply as a widely used food and medical product (Law Library of Congress 2025 [Ref 50]).

---

## Clinical Trials

### Active / Recruiting (as of 2026)
| NCT ID | Title | Phase | Status | Sponsor |
|---|---|---|---|---|
| NCT05357040 | Antidepressant Effects of Nitrous Oxide | Phase 2 | Recruiting | University of Chicago |
| NCT05357066 | Nitrous Oxide as Treatment for Fibromyalgia | Phase 2 | Recruiting | University of Chicago |
| NCT03167905 | CODEPAD (Postpartum Depression and N₂O Analgesia) | Phase 2 | Active, not recruiting | KK Women's and Children's Hospital |

### Completed
| NCT ID | Title | Phase | Sponsor |
|---|---|---|---|
| NCT05007028 | N₂O for Late-Life Depression (PROTO-BRAIN) | N/A | University Hospital, Tours |
| NCT02145169 | N₂O to Prevent Ketamine Emergence Reaction | N/A | Albert Einstein Healthcare |
| NCT02410707 | Adjunctive N₂O During ED Propofol Sedation | N/A | Albert Einstein Healthcare |
| NCT05126459 | Multi-agent Oral Sedation in Pediatric Dental (includes N₂O arm) | Phase 3 | Loma Linda University |

### Terminated / Withdrawn
| NCT ID | Title | Phase | Notes |
|---|---|---|---|
| NCT02351869 | N₂O for Bipolar Disorder | Phase 2 | Terminated (Sunnybrook) |
| NCT05710887 | N₂O for Acute Suicidality and Depression in ED | Phase 2 | Withdrawn (U Chicago) |

**Most important recent trial results:**
- Nagele et al. 2021 (Science Translational Medicine [Ref 13]): Phase 2 crossover RCT (n=24 severe TRMD); 25% N₂O comparable to 50% N₂O in antidepressant efficacy with markedly fewer adverse effects (p<0.001)
- Gill et al. 2025 (EBioMedicine [Ref 29]): Systematic review and meta-analysis of all N₂O antidepressant trials — most comprehensive synthesis to date
- Myles et al. 2025 (Biological Psychiatry Global Open Science [Ref 44]): Phase 2b RCT for MDD (not just TRD)

---

## Community Feedback Analysis

**No community feedback was submitted.** The brief's Part A2 section is empty.

Proceeding with standard research findings only.

---

## Gaps & Flags

### ⚠️ Safety-Critical Flags

1. **Dose/duration: Seed data uses grams (e.g., "Threshold: 4g inhaled").** This is unusual for an inhaled gas typically dosed in percentages or volumes. The "g" dosing likely refers to the mass of N₂O in a cartridge (standard culinary charger = 8g). This dose/unit system should be verified against community sources and confirmed as intentional before publication. No published literature expresses N₂O recreational doses in grams this way.

2. **Tolerance values unverified:** The seed data tolerance values ("half-life: 5 days; full reset: 1.5 weeks") have no published primary source support found in this research. These appear to be community-derived. FLAG for editorial review.

3. **All opioid interactions marked "unknown":** This is accurate — no recreational dose-specific interaction studies exist. However, the mechanism-based risk (additive opioid/CNS depression) is real. These should remain flagged as "unknown" severity, not "safe." Consider adding a note that combinations carry theoretical additive CNS/respiratory depression risk.

4. **B12 deficiency as contraindication:** The seed data's "Contraindications" field is empty. The literature strongly supports adding B12 deficiency/cobalamin metabolism disorders as a contraindication, along with closed gas space pathologies (pneumothorax, bowel obstruction, middle ear disease). This gap should be corrected.

5. **No LD50 data available:** Exact toxic dose is correctly noted in the seed data as unknown. N₂O is an asphyxiant; the primary lethal mechanism is oxygen displacement, not direct toxicity.

### Data Gaps

6. **Ki/EC50 binding affinity data absent:** N₂O's NMDA antagonism potency is conventionally expressed as MAC (atmospheric partial pressure) rather than molecular binding constants. No published Ki or IC₅₀ values found.

7. **No published pharmacokinetic studies at recreational doses:** Human PK data (Tmax, specific plasma concentrations) at sub-anesthetic recreational doses is not available; the gas is not detectable in routine biological assays.

8. **Systematic name/IUPAC:** The brief lists these as empty. Confirmed: IUPAC name = "nitrous oxide" (this is both common and systematic name for a simple inorganic compound).

9. **Subjective effects studies:** No controlled human studies with validated psychedelic/dissociative effect scales (CEQ, 5D-ASC, CADSS) at recreational doses were found. The effects taxonomy in the brief is derived from clinical descriptions, case reports, and survey data.

10. **Cross-tolerance:** No published data on cross-tolerance with ketamine or other dissociatives.

11. **Animal studies vs. human studies:** Several pharmacological findings (SK2 channel: Cichon 2025; noradrenergic pathway: Sawamura 2000; dynorphin: Branda 2000; beta-endorphin: Ohgami 2010) are established in rodent models. Human confirmation for specific molecular mechanisms is limited, though the clinical effects are well-documented.

12. **SMILES field in database:** The seed data SMILES field is empty. Verified SMILES: [N-]=[N+]=O (canonical PubChem representation). This should be populated.

13. **PubChem CID field in database:** Currently empty in seed data. Confirmed value: 948.

Nitrous

Value Provenance

Dosing

inhaledtrace →

Duration

inhaled

Safety

Toxicity Profiletrace →

Dependence Profiletrace →

Withdrawal Profiletrace →

Tolerance Profiletrace →

Effects & Profile

Contraindications

Timeline Phases

inhaled

Dose Tier Summaries

History

Sources

Claim Verification

Coverage & Gaps

Research Trail

inhaledtrace

Toxicity Profiletrace

Dependence Profiletrace

Withdrawal Profiletrace

Tolerance Profiletrace